<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   COVID-19: Vaccines
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       COVID-19: Vaccines
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        COVID-19: Vaccines
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathryn M Edwards, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Walter A Orenstein, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Martin S Hirsch, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Allyson Bloom, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 14, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2043777381">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vaccines to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are considered the most promising approach for curbing the coronavirus disease 2019 (COVID-19) pandemic.
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcovid19.trackvaccines.org%2Fvaccines%2F&amp;token=vJzeJSO96jlIEutymmylc0WAshtsX2AsUgsoIbJZAjXJrh7X9gNmTONJegAI3Bn9&amp;TOPIC_ID=129849" target="_blank">
          Several COVID-19 vaccines
         </a>
         are available globally. The World Health Organization (WHO) maintains an
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fpublications%2Fm%2Fitem%2Fdraft-landscape-of-covid-19-candidate-vaccines&amp;token=e%2FAHRv%2BhUp7GBKbt2E2klHXJQDV6naHtazpeKeuaONlvcSTF0twhvGV1HNYgmIzb4olt5YlWsC7XXC7SV5%2FjIt4sz0vGq%2FHpcdZMn5B%2FIXivALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=129849" target="_blank">
          updated list
         </a>
         of vaccine candidates under evaluation and available for administration [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         This topic will cover vaccines for SARS-CoV-2, with a focus on vaccines available in the United States. Other aspects related to the prevention of COVID-19 are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">
          "COVID-19: Epidemiology, virology, and prevention", section on 'Prevention'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2122640867">
         <span class="h1">
          GENERAL PRINCIPLES
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pace of COVID-19 vaccine development
         </strong>
         – Although COVID-19 vaccine development has been accelerated, each vaccine that has received emergency use listing by the World Health Organization (WHO; which includes those that have been authorized or approved in the United States) has gone through the standard preclinical and clinical stages of development. Safety criteria have remained stringent; data safety and monitoring committees (DSMCs) composed of independent vaccine experts and study sponsors assess adverse events that are reported in each phase of clinical study and approve advancement to the next phase.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Calculation of vaccine efficacy
         </strong>
         – Vaccine efficacy in percent is the reduction in disease incidence among those who received vaccine versus those who received the control product and is calculated with the following formula:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         ([attack rate in the unvaccinated – attack rate in the vaccinated]/attack rate in the unvaccinated) x 100, often abbreviated as ([ARU – ARV]/ARU) x 100
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antigenic target
         </strong>
         – The major antigenic target for COVID-19 vaccines is the surface spike protein  (
         <a class="graphic graphic_figure graphicRef130132" href="/z/d/graphic/130132.html" rel="external">
          figure 1
         </a>
         ). It binds to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells and induces membrane fusion  (
         <a class="graphic graphic_figure graphicRef130134" href="/z/d/graphic/130134.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. Antibodies binding to the receptor-binding domain of the SARS-CoV-2 spike protein prevent attachment to the host cell and neutralize the virus [
         <a href="#rid3">
          3
         </a>
         ]. Over time, the messenger ribonucleic acid (mRNA) vaccines have been reformulated to target the mutations in the spike proteins of the various SARS-CoV-2 variants. (See
         <a class="local">
          'Available vaccines'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vaccine platforms
         </strong>
         – COVID-19 vaccines have been and are being developed using several different platforms [
         <a href="#rid3">
          3
         </a>
         ]. Some of these are traditional approaches, such as inactivated virus or live attenuated viruses, which have been used for influenza vaccines and measles vaccines, respectively. Other approaches employ newer platforms, such as recombinant proteins (used for human papillomavirus vaccines) and vectors (used for Ebola vaccines). Some platforms, such as mRNA and DNA (deoxyribonucleic acid) vaccines, had never been employed in a licensed vaccine prior to the COVID-19 vaccine. General descriptions of the different platforms used for COVID-19 vaccines are presented in the table  (
         <a class="graphic graphic_table graphicRef135003" href="/z/d/graphic/135003.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Site of delivery and immune response
         </strong>
         – COVID-19 vaccines have been demonstrated to elicit a sufficient neutralizing response to protect against COVID-19. The site of vaccine delivery may impact the character of the immune response [
         <a href="#rid3">
          3
         </a>
         ]. Natural respiratory infections elicit both mucosal and systemic immune responses. Most respiratory virus vaccines, however, are administered intramuscularly (or intradermally) and elicit primarily a systemic immune response, with less robust protection in the upper respiratory mucosa than after natural infection. Some live-attenuated respiratory virus vaccines can be administered intranasally, approximating natural infection, and these may elicit additional mucosal immune responses, although they typically do not induce as high of a systemic antibody response as inactivated vaccines when administered systemically [
         <a href="#rid4">
          4,5
         </a>
         ]. Live-attenuated COVID-19 vaccines administered to the respiratory tract are under development.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vaccine-enhanced disease
         </strong>
         – Animal studies of certain vaccines for SARS-CoV-1 (severe acute respiratory syndrome coronavirus 1) and MERS-CoV (Middle East respiratory syndrome-related coronavirus) raised concerns for enhanced disease with vaccination when some vaccinated animals developed non-neutralizing antibody and Th2 cell responses that were associated with eosinophilic lung inflammation following challenge with wild-type virus [
         <a href="#rid6">
          6-8
         </a>
         ]. No vaccine-enhanced disease was seen in any human COVID-19 vaccine studies. Nevertheless, specific immunologic parameters were targeted for animal and human studies to reduce the risk of enhanced disease [
         <a href="#rid9">
          9
         </a>
         ]. The desired immune responses included neutralizing antibody and Th1-polarized cellular immune responses.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2954972485">
         <span class="h1">
          APPROACH TO VACCINATION IN THE UNITED STATES
         </span>
        </p>
        <p class="headingAnchor" id="H3186778813">
         <span class="h2">
          Available vaccines
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the United States, three COVID-19 vaccines are available  (
         <a class="graphic graphic_table graphicRef130711" href="/z/d/graphic/130711.html" rel="external">
          table 2
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two mRNA vaccines
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Moderna COVID-19 vaccine
         </a>
         <strong>
          (2023-2024 Formula, based on XBB.1.5)
         </strong>
         – This is approved for individuals 12 years and older and available under emergency use authorization (EUA) for children aged 6 months to 11 years [
         <a href="#rid10">
          10,11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Pfizer-BioNTech COVID-19 vaccine
         </a>
         <strong>
          (2023-2024 Formula, based on XBB.1.5)
         </strong>
         – This is approved for individuals 12 years and older and available under EUA for children aged 6 months to 11 years [
         <a href="#rid12">
          12,13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Each mRNA vaccine began as a monovalent formulation with an antigenic target based on the original Wuhan SARS-CoV-2 strain. In September 2022, bivalent formulations with antigenic targets based on the original Wuhan SARS-CoV-2 strain and the BA.4/BA.5 Omicron subvariants were also introduced and became the only mRNA COVID-19 vaccine formulations available in April 2023. As of September 2023, the bivalent formulations were replaced with a monovalent formulation with an antigenic target based on the XBB.1.5 Omicron variant. That variant was selected as the model for the updated formulation in the summer of 2023, based on projections for fall 2023 variant proportions [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An adjuvanted recombinant protein vaccine (monovalent):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="135147" href="/z/d/drug information/135147.html" rel="external">
          Novavax COVID-19 vaccine
         </a>
         <strong>
          , adjuvanted (2023-2024 Formula)
         </strong>
         – This is available under EUA for individuals aged 12 years or older [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The Novavax COVID-19 has also been updated to target the XBB.1.5 Omicron variant.
        </p>
        <p>
        </p>
        <p>
         As of May 2023, all doses of the adenoviral vector vaccine
         <a class="drug drug_general" data-topicid="130461" href="/z/d/drug information/130461.html" rel="external">
          Janssen/Johnson &amp; Johnson COVID-19 vaccine
         </a>
         (Ad26.COV2.S) have expired [
         <a href="#rid16">
          16
         </a>
         ], and this vaccine is no longer available in the United States.
        </p>
        <p class="headingAnchor" id="H3702346090">
         <span class="h2">
          Indications and vaccine selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest COVID-19 vaccination with a 2023-2024 formula vaccine for all individuals aged six months and older; this is consistent with recommendations from the Centers for Disease Control and Prevention (CDC). We particularly encourage vaccination in individuals 65 years or older, immunocompromised individuals, and individuals with multiple medical comorbidities, as they are at highest risk of severe outcomes with COVID-19 and are most likely to benefit from vaccination  (
         <a class="graphic graphic_table graphicRef127477" href="/z/d/graphic/127477.html" rel="external">
          table 3
         </a>
         ). In the United States, the available vaccines are
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Moderna COVID-19 vaccine
         </a>
         2023-2024 Formula, Pfizer COVID-19 vaccine 2023-2024 Formula, and
         <a class="drug drug_general" data-topicid="135147" href="/z/d/drug information/135147.html" rel="external">
          Novavax COVID-19 vaccine
         </a>
         2023-2024 Formula  (
         <a class="graphic graphic_table graphicRef130711" href="/z/d/graphic/130711.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         Vaccines available in the United States reduce the risk of COVID-19, especially severe/critical disease, and have been associated with substantial reductions in COVID-19-associated hospitalizations and deaths [
         <a href="#rid17">
          17-24
         </a>
         ], even in the context of variants that partially evade vaccine-induced immune responses. The vaccines are safe, with only very rare associated severe adverse events. The benefits and potential risks of vaccines are discussed elsewhere. (See
         <a class="local">
          'Benefits of vaccination'
         </a>
         below and
         <a class="local">
          'Risks of vaccination'
         </a>
         below.)
        </p>
        <p>
         Although the risk of severe disease has decreased substantially since the start of the pandemic, COVID-19 remains an important cause of hospitalization and death, with the highest rates in individuals older than 65 years or younger than six months. In the United States, COVID-19-associated hospitalizations substantially exceeded influenza-associated hospitalizations for all individuals in 2022 and for adults in the first half of 2023. A similar proportion of either COVID-19- or influenza-associated hospitalizations results in intensive care unit (ICU) admission and death [
         <a href="#rid25">
          25
         </a>
         ]. Although most individuals with COVID-19-associated hospitalization have medical comorbidities (and most hospitalized adults have multiple comorbidities), approximately 40 to 60 percent of hospitalized children aged six months to four years have no underlying conditions, and 15 to 50 percent of those aged 6 months to 49 years admitted to the ICU had no underlying conditions. Thus, although the potential benefit of COVID-19 vaccination in reducing the risk of severe disease is greatest in those at highest risk, the risk of severe disease exists for all individuals.
        </p>
        <p class="headingAnchor" id="H467782694">
         <span class="h2">
          Dose and interval (for immunocompetent individuals)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vaccine dosing and intervals are also listed in the table  (
         <a class="graphic graphic_table graphicRef130711" href="/z/d/graphic/130711.html" rel="external">
          table 2
         </a>
         ). Recommended vaccine schedules for individuals with immunocompromising conditions are discussed elsewhere. (See
         <a class="local">
          'Immunocompromised individuals'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2293085454">
         <span class="h3">
          Children aged six months to four years
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children under five years of age, 2023-2024 formula mRNA vaccines are recommended for all vaccine doses [
         <a href="#rid26">
          26
         </a>
         ]. The dosing schedule depends on their prior COVID-19 vaccination status.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For immunocompetent children who have not previously received a COVID-19 vaccine:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Moderna COVID-19 vaccine
         </a>
         (2023-2024 Formula) – Two intramuscular doses of 25 mcg (0.25 mL of the dark blue capped vial) given four to eight weeks apart [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Pfizer COVID-19 vaccine
         </a>
         (2023-2024 Formula) – Three intramuscular doses of 3 mcg (0.3 mL of the yellow capped vial) [
         <a href="#rid12">
          12
         </a>
         ]. The first two doses are given three to eight weeks apart, and the third dose is given at least eight weeks after the second.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For immunocompetent children who have previously received at least one vaccine dose, the number of subsequent doses with the 2023-2024 formula mRNA vaccines depends on how many doses and which vaccine they had previously received:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prior
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Moderna COVID-19 vaccine
         </a>
         doses [
         <a href="#rid10">
          10
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Those who have received a single prior dose receive a single intramuscular dose of 25 mcg (0.25 mL of the dark blue-capped vial)
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Moderna COVID-19 vaccine
         </a>
         (2023-2024 Formula) four to eight weeks later.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Those who have received two or more prior doses receive a single intramuscular dose of 25 mcg (0.25 mL of the dark blue-capped vial)
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Moderna COVID-19 vaccine
         </a>
         (2023-2024 Formula) at least eight weeks after the last dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prior
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Pfizer COVID-19 vaccine
         </a>
         doses [
         <a href="#rid12">
          12
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Those who have received a single prior dose receive two intramuscular doses of 3 mcg (0.3 mL of the yellow-capped vial)
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Pfizer COVID-19 vaccine
         </a>
         (2023-2024 Formula): one dose three weeks after the last dose and a second dose at least eight weeks later.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Those who have received two or more prior doses receive a single intramuscular dose of 3 mcg (0.3 mL of the yellow-capped vial)
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Pfizer COVID-19 vaccine
         </a>
         (2023-2024 Formula). It is given at least eight weeks after the last dose.
        </p>
        <p>
        </p>
        <p>
         Immunocompetent children in this age group who have received at least two doses of
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Moderna COVID-19 vaccine
         </a>
         , at least one of which is the 2023-2024 formula mRNA vaccine, or at least three doses of Pfizer COVID-19 vaccine, at least one of which is the 2023-2024 formula mRNA vaccine, do not need additional vaccinations. All vaccine doses should be from the same manufacturer [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         Vaccine recommendations for children with immunocompromising conditions  (
         <a class="graphic graphic_table graphicRef132490" href="/z/d/graphic/132490.html" rel="external">
          table 4
         </a>
         ) are discussed in detail elsewhere [
         <a href="#rid26">
          26
         </a>
         ]. (See
         <a class="local">
          'Immunocompromised individuals'
         </a>
         below.)
        </p>
        <p>
         Clinical data evaluating COVID-19 vaccine effectiveness in young children are limited. Support for their use comes mainly from immunogenicity bridging studies, some unpublished, in these age groups. (See
         <a class="local">
          'Children'
         </a>
         below.)
        </p>
        <p>
         Although a single mRNA vaccine dose is recommended for other age groups, serologic surveillance suggests that young children in the United States are less likely to have pre-existing immunity (whether from infection or vaccination) than older children and adults, so they may be more likely to need more than one dose to maximize immunogenicity [
         <a href="#rid27">
          27
         </a>
         ]. Additionally, a prime-boost model of vaccination in general is considered important for optimizing vaccine response in young children.
        </p>
        <p class="headingAnchor" id="H4039137807">
         <span class="h3">
          Children aged 5 to 11 years
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children aged 5 to 11 years, a single dose of a 2023-2024 formula mRNA vaccine is recommended, regardless of whether the recipient is unvaccinated or had previously received one or more vaccine doses [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Moderna COVID-19 vaccine
         </a>
         (2023-2024 Formula) – A single intramuscular dose of 25 mcg (0.25 mL of the dark blue-capped vial) [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Pfizer COVID-19 vaccine
         </a>
         (2023-2024 Formula) – A single intramuscular dose of 10 mcg (0.3 mL of the blue-capped vial) [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Vaccine recommendations for children with immunocompromising conditions  (
         <a class="graphic graphic_table graphicRef132490" href="/z/d/graphic/132490.html" rel="external">
          table 4
         </a>
         ) are discussed in detail elsewhere [
         <a href="#rid26">
          26
         </a>
         ]. (See
         <a class="local">
          'Immunocompromised individuals'
         </a>
         below.)
        </p>
        <p>
         Prior recommendations had included a two-dose vaccine series for unvaccinated individuals. However, seroprevalence data suggest that the vast majority (over 96 percent) of individuals in the United States have pre-existing immunity to SARS-CoV-2, either through vaccination or infection [
         <a href="#rid27">
          27
         </a>
         ]. Thus, a single vaccine dose, which has been associated with increases in relative effectiveness against infection and severe disease in individuals with pre-existing immunity from prior vaccination, is expected to be sufficient to improve protection for immunocompetent individuals who have not yet been vaccinated. (See
         <a class="local">
          'Protection against severe disease or death'
         </a>
         below.)
        </p>
        <p>
         Rationale for vaccination in children is discussed elsewhere. (See
         <a class="local">
          'Children'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H294958262">
         <span class="h3">
          Adolescents and adults aged 12 years and older
         </span>
         <span class="headingEndMark">
          —
         </span>
         For individuals older than 12 years of age, a single dose of a 2023-2024 formula mRNA vaccine is recommended, regardless of whether the recipient is unvaccinated or had previously received one or more vaccine doses [
         <a href="#rid26">
          26
         </a>
         ]. If the individual had received prior vaccine doses, the 2023-2024 formula vaccine dose is given at least two months after the last dose:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Moderna COVID-19 vaccine
         </a>
         (2023-2024 Formula) – A single intramuscular dose of 50 mcg (0.5 mL) [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Pfizer COVID-19 vaccine
         </a>
         (2023-2024 Formula) – A single intramuscular dose of 30 mcg (0.3 mL) [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The
         <a class="drug drug_general" data-topicid="135147" href="/z/d/drug information/135147.html" rel="external">
          Novavax COVID-19 vaccine
         </a>
         (2023-2024 Formula) is another option for this age group. For individuals who have not previously received a COVID-19 vaccine, it is given as two intramuscular doses of 5 mcg spike protein/50 mcg adjuvant three to eight weeks apart; for individuals who have received at least one prior COVID-19 vaccine but not a 2023-2024 formula vaccine, it is given as a single dose at least two months after the last dose [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         Vaccine recommendations for individuals with immunocompromising conditions  (
         <a class="graphic graphic_table graphicRef132490" href="/z/d/graphic/132490.html" rel="external">
          table 4
         </a>
         ) are discussed in detail elsewhere [
         <a href="#rid26">
          26
         </a>
         ]. (See
         <a class="local">
          'Immunocompromised individuals'
         </a>
         below.)
        </p>
        <p>
         Although prior recommendations had included a two-dose primary series for unvaccinated individuals, seroprevalence data suggest that the vast majority (over 96 percent) of individuals in the United States have pre-existing immunity to SARS-CoV-2, either through vaccination or infection [
         <a href="#rid28">
          28,29
         </a>
         ]. Thus, a single vaccine dose, which has been associated with increases in relative effectiveness against infection and severe disease in individuals with pre-existing immunity from prior vaccination, is expected to be sufficient to improve protection in immunocompetent individuals without a history of COVID-19 vaccination. More than one dose of a 2023-2024 formula vaccine is not recommended for immunocompetent adults, regardless of age.
        </p>
        <p>
         Among individuals who have already been vaccinated, the rationale for an additional updated vaccine dose is to restore protection that wanes with time and to try to improve the immune response against currently circulating viral variants. This is especially relevant in adults ≥65 years old, among whom the rate of COVID-19-associated hospitalization and death is higher than in any other age group [
         <a href="#rid30">
          30
         </a>
         ]. In the United States, approximately 95 percent of adults ≥65 years old have received a complete primary COVID-19 vaccine series [
         <a href="#rid27">
          27
         </a>
         ], so an additional vaccine dose serves as booster dose, which has been associated with increases in relative effectiveness against infection and severe disease, as discussed in detail elsewhere. (See
         <a class="local">
          'Protection against severe disease or death'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2898232869">
         <span class="h2">
          Other administration issues
         </span>
        </p>
        <p class="headingAnchor" id="H2309810845">
         <span class="h3">
          Technique and potential administration errors
         </span>
         <span class="headingEndMark">
          —
         </span>
         In adults and adolescents, intramuscular vaccines are typically injected into the deltoid. Proper injection technique to reduce the risk of shoulder injury involves injection at a 90° angle into the central, thickest part of the deltoid  (
         <a class="graphic graphic_figure graphicRef114648" href="/z/d/graphic/114648.html" rel="external">
          figure 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/3884.html" rel="external">
          "Standard immunizations for nonpregnant adults", section on 'Technique'
         </a>
         .)
        </p>
        <p>
         Additional details on administration can be found on the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Fclinical-considerations%2Finterim-considerations-us-appendix.html&amp;token=JEHHJm%2FVE%2Fczu0Kvc1DVQUpygFBTbM3nx%2BQkzEPu166b1PdyYB%2FZy8UUx%2BhLrk1M6M7adxMuNRwuLsclowR%2BInMu5rgfG6pvkqGlpyWY%2BzeDWuJXy7rpwtTo6vB9J89C&amp;TOPIC_ID=129849" target="_blank">
          CDC website
         </a>
         . The following table details CDC recommendations on the management of vaccine administration errors  (
         <a class="graphic graphic_table graphicRef130956" href="/z/d/graphic/130956.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H787546020">
         <span class="h3">
          Mixing vaccine types
         </span>
         <span class="headingEndMark">
          —
         </span>
         For individuals six years of age and older who had previously received an older monovalent or bivalent vaccine, any of the 2023-2024 formula vaccines can be subsequently used; they do not have to use the vaccine from the same manufacturer as the original doses. (See
         <a class="local">
          'Dose and interval (for immunocompetent individuals)'
         </a>
         above.)
        </p>
        <p>
         For those who received a non-mRNA vaccine for the primary series, studies indicate robust antibody responses with an mRNA booster dose (ie, a heterologous boost) [
         <a href="#rid31">
          31-33
         </a>
         ] and greater effectiveness than with homologous boosting [
         <a href="#rid34">
          34-36
         </a>
         ]. As an example, in a study of nearly five million United States veterans, receipt of an mRNA vaccine boost after a primary
         <a class="drug drug_general" data-topicid="130461" href="/z/d/drug information/130461.html" rel="external">
          Janssen/Johnson &amp; Johnson COVID-19 vaccine
         </a>
         dose was associated with a lower risk of infection than receipt of a Janssen/Johnson &amp; Johnson COVID-19 vaccine boost (adjusted rate ratio 0.49); for mRNA vaccine recipients, there was not a substantial difference in infection rates in recipients of a homologous mRNA boost versus a heterologous mRNA boost [
         <a href="#rid34">
          34
         </a>
         ]. Immunogenicity studies support these findings and suggested higher binding and neutralizing antibody levels with a
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Moderna COVID-19 vaccine
         </a>
         boost than with a Pfizer COVID-19 vaccine boost [
         <a href="#rid32">
          32
         </a>
         ]. No safety concerns were identified; the frequency and duration of systemic symptoms (eg, fever, chills, myalgias) may be slightly higher with Moderna COVID-19 vaccine booster doses.
        </p>
        <p class="headingAnchor" id="H2453355212">
         <span class="h3">
          Timing with relation to non-COVID-19 vaccines
         </span>
         <span class="headingEndMark">
          —
         </span>
         The CDC specifies that COVID-19 vaccines can be administered at any time in relation to most other non-COVID-19 vaccines and, if needed, can be administered simultaneously with other vaccines [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Coadministration
         </strong>
         – When coadministered, each vaccine should be injected in different sites separated by at least one inch (and vaccines that are associated with local reactions should ideally be injected in a different limb than COVID-19 vaccines). Limited data suggest that coadministration of COVID-19 vaccines with certain other vaccines is likely safe. In a randomized trial, frequency of adverse effects and immunogenicity were largely similar when a COVID-19 vaccine was given concomitantly with either an influenza vaccine or placebo [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Additional considerations with orthopoxvirus vaccination
         </strong>
         – For individuals who have received an orthopoxvirus vaccine to prevent mpox (formerly known as monkeypox), particularly adolescent or young adult males, the CDC suggests that it is reasonable to defer COVID-19 vaccination for four weeks because of the uncertain risk of myocarditis with closely spaced administration [
         <a href="#rid26">
          26
         </a>
         ]. However, recent COVID-19 vaccination should not delay orthopoxvirus vaccination if indicated, given the potential health burden of mpox in the at-risk population.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4280045364">
         <span class="h3">
          Limited role for post-vaccination testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Unless indicated to evaluate for suspected infection, there is no role for routine post-vaccination testing for COVID-19. Specifically, serologic testing following vaccination to confirm an antibody response or to determine whether to give additional doses of vaccine (eg, booster doses) is not indicated. Many serologic tests will not detect the type of antibodies elicited by vaccination. This is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/128404.html" rel="external">
          "COVID-19: Diagnosis", section on 'Testing following COVID-19 vaccination'
         </a>
         .)
        </p>
        <p>
         Some side effects of vaccination overlap with symptoms of COVID-19. Systemic reactions (eg, fever, chills, fatigue, headache) that occur within the first day or two after vaccination and resolve within a day or two are consistent with a reaction to the vaccine. However, respiratory symptoms or systemic symptoms that occur after the first couple of days following vaccination or that last several days could be indicative of COVID-19 and warrant testing. (See
         <a class="medical medical_review" href="/z/d/html/128404.html" rel="external">
          "COVID-19: Diagnosis", section on 'Choosing an initial diagnostic test'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2002843425">
         <span class="h2">
          Considerations for special populations
         </span>
        </p>
        <p class="headingAnchor" id="H2995516486">
         <span class="h3">
          History of SARS-CoV-2 infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest eligible individuals with a history of SARS-CoV-2 infection receive a COVID-19 vaccine; pre-vaccination serologic screening to identify prior infection is not recommended [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Timing of vaccination
         </strong>
         – Individuals with recent, documented SARS-CoV-2 infection (including those who are diagnosed after initiating a vaccine series) should have at least recovered from acute infection and met criteria for discontinuation of isolation precautions before receiving a vaccine dose. Additionally, given the low risk of reinfection soon after prior infection, it is reasonable for individuals with SARS-CoV-2 infection to wait to receive a vaccine dose until three months after infection [
         <a href="#rid26">
          26
         </a>
         ]. Potential reasons not to delay the vaccine dose in this population include high risk for severe infection, high rates of community transmission, and circulating variants associated with a high risk of reinfection. (See
         <a class="local">
          'Other administration issues'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Individuals with a history of MIS
         </strong>
         – For individuals who had SARS-CoV-2 infection complicated by multisystem inflammatory syndrome (MIS), the decision to vaccinate should be individualized and weigh the risk of exposure, reinfection, and severe disease with infection against the uncertain safety of vaccination in such individuals. Given the hypothesis that MIS is associated with immune dysregulation precipitated by SARS-CoV-2 infection, it is unknown if a SARS-CoV-2 vaccine could trigger a similar dysregulated response. Nevertheless, the benefits of vaccination may outweigh the risk among those with a history of MIS if they have recovered clinically, had MIS ≥90 days previously, are at increased risk for SARS-CoV-2 exposure, and if the MIS was not associated with COVID-19 vaccination [
         <a href="#rid26">
          26
         </a>
         ]. In a study of 186 individuals ≥5 years old with a history of MIS ≥90 days prior to vaccine receipt, the side effect profile of mRNA vaccination was similar to that in the general population; no cases of myocarditis or recurrent MIS were observed [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Vaccination is still beneficial in many patients with a history of SARS-CoV-2 infection. Vaccination appears to further boost antibody levels and cell-mediated responses in those with past infection and likely improves the durability and breadth of protection [
         <a href="#rid39">
          39-41
         </a>
         ]. In multiple observational studies of individuals with prior infection, vaccination has been associated with a lower risk of subsequent reinfection and hospitalization [
         <a href="#rid42">
          42-49
         </a>
         ]; it has also been associated with a lower risk of breakthrough infection compared with vaccination in individuals without prior infection [
         <a href="#rid50">
          50,51
         </a>
         ].
        </p>
        <p>
         Vaccination has been associated with greater protection against hospitalization for COVID-19 compared with prior infection in some studies [
         <a href="#rid52">
          52
         </a>
         ]. However, one study suggested that when the Delta variant was prevalent, prior infection was associated with greater protection against COVID-19-related hospitalization than vaccination, although vaccination was still protective; estimates were age adjusted, but this study did not account for other potential confounders that may affect hospitalization risk (eg, comorbidities, exposure risk) [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
         Among individuals who have persistent symptoms following acute COVID-19, vaccination has been associated with a higher likelihood of symptom improvement compared with no vaccination, according to a systematic review by the United Kingdom Health Security Agency; however, for most individuals, symptoms remain unchanged regardless of vaccination [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         Individuals with a history of SARS-CoV-2 may be more likely to experience local and systemic adverse effects (eg, fevers, chills, myalgias, fatigue) after a first vaccine dose than SARS-CoV-2-naïve individuals [
         <a href="#rid26">
          26,55,56
         </a>
         ]. This is not a contraindication or precaution for subsequent vaccine doses.
        </p>
        <p class="headingAnchor" id="H2581780960">
         <span class="h3">
          Recent SARS-CoV-2 exposure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with a known SARS-CoV-2 exposure should receive COVID-19 vaccination, as recommended for the general population. However, such individuals who are in the community should wait until they have completed their postexposure quarantine period to avoid inadvertent exposures to others in the event of infection [
         <a href="#rid26">
          26
         </a>
         ]. Individuals who are exposed to SARS-CoV-2 in a congregate residential setting can receive COVID-19 vaccination without delay.
        </p>
        <p>
         Given that the time needed to generate a protective immune response following vaccination exceeds the mean incubation period of SARS-CoV-2, postexposure vaccination would likely not reduce the risk of infection following that specific exposure.
        </p>
        <p class="headingAnchor" id="H1291093171">
         <span class="h3">
          Immunocompromised individuals
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend that individuals who have an immunocompromising condition or are taking immunosuppressive agents undergo COVID-19 vaccination  (
         <a class="graphic graphic_table graphicRef132490" href="/z/d/graphic/132490.html" rel="external">
          table 4
         </a>
         ). Immunogenicity and effectiveness of COVID-19 vaccines appear lower in such individuals compared with the general population; nevertheless, the potential for severe COVID-19 in this population outweighs the uncertainties. Given the potential for reduced vaccine response in such individuals, the recommended vaccine schedule is distinct, as outlined below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Conditions that warrant an adjusted vaccine schedule
         </strong>
         – Moderate to severe immunocompromising conditions that warrant a modified vaccine schedule include active use of chemotherapy for cancer, hematologic malignancies, hematopoietic stem cell or solid organ transplant, advanced HIV (human immunodeficiency virus) infection with CD4 cell count &lt;200 cells/microL or untreated HIV, moderate or severe primary immunodeficiency disorder, and use of immunosuppressive medications (eg,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         &gt;20 mg/day for &gt;14 days)  (
         <a class="graphic graphic_table graphicRef132490" href="/z/d/graphic/132490.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid57">
          57
         </a>
         ]. This list is not exhaustive, however; other conditions, such as impaired splenic function [
         <a href="#rid58">
          58
         </a>
         ], may also warrant additional vaccine doses than recommended in the general population.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Data suggest that COVID-19 vaccines are effective in many immunocompromised patients, even in the context of the Omicron variant, although they are less so than in individuals without compromised immune systems [
         <a href="#rid59">
          59-66
         </a>
         ]. In a cohort study of over one million individuals who had received at least one mRNA vaccine in Israel, vaccine effectiveness for symptomatic COVID-19 was 75 percent (95% CI 44-88) among immunocompromised patients compared with 94 percent (95% CI 87-97) overall [
         <a href="#rid59">
          59
         </a>
         ]. Lower vaccine effectiveness against hospitalization for COVID-19 in immunocompromised patients has also been suggested by smaller case-control studies [
         <a href="#rid60">
          60
         </a>
         ]. In studies of individuals hospitalized with COVID-19 despite vaccination, a high proportion (eg, 40 percent) have been immunocompromised [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In particular, transplant recipients and individuals taking B cell-depleting agents (particularly within the prior six months) may have a suboptimal vaccine response [
         <a href="#rid65">
          65,67-72
         </a>
         ]. Among transplant recipients, factors associated with a higher rate of nonresponse include use of antimetabolites (eg,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ) and a shorter time since transplantation. (See
         <a class="medical medical_review" href="/z/d/html/127582.html" rel="external">
          "COVID-19: Issues related to solid organ transplantation", section on 'Vaccination'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Recommended vaccine series in immunocompromised individuals
         </strong>
         – The CDC recommends that individuals with moderate to severe immunocompromising conditions  (
         <a class="graphic graphic_table graphicRef132490" href="/z/d/graphic/132490.html" rel="external">
          table 4
         </a>
         ) receive at least three vaccine doses, at least one of which is a 2023-2024 formula mRNA vaccine (
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Moderna COVID-19 vaccine
         </a>
         2023-2024 Formula or Pfizer COVID-19 vaccine 2023-2024 Formula). Thus, initial vaccine recommendations depend on the vaccination history:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Unvaccinated individuals should receive three 2023-2024 formula vaccine doses.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         If
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Moderna COVID-19 vaccine
         </a>
         is used, the second dose is given four weeks after the first and the third is given at least four weeks later.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         If
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Pfizer COVID-19 vaccine
         </a>
         is used, the second dose is given three weeks after the first, and the third is given at least eight weeks later (for individuals six months to four years of age) or at least four weeks later (for individuals five years of age and older).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Individuals who have received only one previous vaccine dose should receive two 2023-2024 formula vaccine doses.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         If
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Moderna COVID-19 vaccine
         </a>
         is used, the first 2023-2024 formula dose is given four weeks after the last vaccine dose, and the second 2023-2024 formula dose is given at least four weeks later.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         If
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Pfizer COVID-19 vaccine
         </a>
         is used, the first 2023-2024 formula dose is given three weeks after the last vaccine dose, and the second 2023-2024 formula dose is given at least eight weeks later (for individuals six months to four years of age) or at least four weeks later (for individuals five years of age and older).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Individuals who have received two or more previous vaccine doses should receive one 2023-2024 formula vaccine dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For those who received two prior vaccine doses, the 2023-2024 formula vaccine dose is given at least four weeks after the last dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For those who received three or more prior vaccine doses, the 2023-2024 formula vaccine dose is given at least eight weeks after the last dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The specific dose given for each vaccine depends on the age of the individual and is the same as for individuals without immunocompromising conditions  (
         <a class="graphic graphic_table graphicRef130711" href="/z/d/graphic/130711.html" rel="external">
          table 2
         </a>
         ). For individuals aged 12 years and older, the
         <a class="drug drug_general" data-topicid="135147" href="/z/d/drug information/135147.html" rel="external">
          Novavax COVID-19 vaccine
         </a>
         (2023-2024 Formula) is another option.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Support for multiple vaccine doses for individuals with immunocompromising conditions comes from multiple observational studies in which receipt of three doses of mRNA monovalent vaccines was associated with higher vaccine effectiveness than two doses [
         <a href="#rid73">
          73,74
         </a>
         ]. In studies of transplant recipients who received a third dose of mRNA monovalent vaccines, seroconversion rates were higher after the additional dose, although approximately 50 to 70 percent who were seronegative after two doses remained seronegative; adverse effects were similar to those reported after prior doses [
         <a href="#rid75">
          75-79
         </a>
         ]. Receipt of an additional dose following three doses of an mRNA vaccine (akin to a booster dose after a three-dose primary series) has also been associated with improved seroconversion rates [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Additional vaccine doses in individuals who have received at least three vaccine doses, including at least one 2023-2024 formula vaccine dose
         </strong>
         – For individuals with moderate to severe immunocompromising conditions  (
         <a class="graphic graphic_table graphicRef132490" href="/z/d/graphic/132490.html" rel="external">
          table 4
         </a>
         ) who have received the vaccines recommended above, the CDC allows for an additional 2023-2024 formula vaccine dose at least two months later.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We individualize the decision to administer this additional dose and are more likely to suggest it for individuals with expected high risk of exposure and profound immunosuppression (such as B cell depletion, recent or complicated hematopoietic stem cell transplant [HCT], or chimeric antigen receptor [CAR]-T cell therapy). The clinical effect of multiple 2023-2024 formula vaccines is uncertain, and data are limited. The rationale is that, in such patients, repeated vaccination can boost the immune response. (See
         <a class="local">
          'Protection against severe disease or death'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Timing immunosuppressive agents and vaccination
         </strong>
         – Some expert groups recommend holding certain immunosuppressive agents around the time of vaccination or adjusting the timing of vaccination to account for receipt of such agents to try to optimize the vaccine response. As an example, for patients receiving
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , the American College of Rheumatology suggests scheduling vaccination so that the series is initiated approximately four weeks prior to the next scheduled rituximab dose and delaying administration of rituximab until two to four weeks after completion of vaccination, if disease activity allows [
         <a href="#rid81">
          81
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/127933.html" rel="external">
          "COVID-19: Care of adult patients with systemic rheumatic disease", section on 'COVID-19 vaccination while on immunosuppressive therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Revaccination following certain immunosuppressing therapies
         </strong>
         – For those who received COVID-19 vaccination prior to hematopoietic stem cell transplant (HCT) or chimeric antigen receptor (CAR)-T cell therapy, the CDC recommends repeat vaccination at least three months after the transplant or CAR-T administration [
         <a href="#rid26">
          26
         </a>
         ]. For those who were vaccinated during a limited course of a B cell-depleting therapy, repeat vaccination is suggested six months following therapy. (See
         <a class="medical medical_review" href="/z/d/html/3882.html" rel="external">
          "Immunizations in hematopoietic cell transplant candidates and recipients"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continued use of protective measures
         </strong>
         – We advise immunocompromised patients to maintain personal measures to try to minimize exposure to SARS-CoV-2 (eg, avoiding crowds when possible, masking if the likelihood of exposure is high) even after they have been vaccinated because of the potential for reduced vaccine effectiveness. Household and other close contacts of immunocompromised patients should be vaccinated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Limited role for post-vaccination serology
         </strong>
         – At this time, antibody testing is not recommended to determine response to vaccination [
         <a href="#rid26">
          26
         </a>
         ]. Precise immune correlates of protection against severe disease remain uncertain; vaccination may elicit cellular but not humoral responses among some immunocompromised patients, and those responses may protect against severe infection [
         <a href="#rid82">
          82
         </a>
         ]. Furthermore, heterogeneity in the sensitivity and specificity of available serologic tests complicates interpretation of results. (See
         <a class="local">
          'Antibody responses and immune correlates of protection'
         </a>
         below and
         <a class="local">
          'Limited role for post-vaccination testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         Issues related to vaccination of specific immunocompromised populations are discussed in detail elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/128993.html" rel="external">
          "COVID-19: Considerations in patients with cancer", section on 'COVID-19 vaccination'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/127933.html" rel="external">
          "COVID-19: Care of adult patients with systemic rheumatic disease", section on 'COVID-19 vaccination while on immunosuppressive therapy'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/127582.html" rel="external">
          "COVID-19: Issues related to solid organ transplantation", section on 'Vaccination'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/106521.html" rel="external">
          "Immunizations in patients with inborn errors of immunity", section on 'Issues related to SARS-CoV-2 vaccination'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H613568992">
         <span class="h3">
          Pregnant individuals
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vaccine recommendations for the general population extend to pregnant individuals as well. Data on safety and efficacy of COVID-19 vaccination in individuals who are pregnant or breastfeeding are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/127535.html" rel="external">
          "COVID-19: Overview of pregnancy issues", section on 'Vaccination in people planning pregnancy and pregnant or recently pregnant people'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4062268164">
         <span class="h3">
          Children
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend that eligible children undergo COVID-19 vaccination. Dosing in children depends on age and is discussed elsewhere. (See
         <a class="local">
          'Dose and interval (for immunocompetent individuals)'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefits of COVID-19 vaccination in children
         </strong>
         – COVID-19 vaccination is associated with reductions in severe adverse outcomes related to COVID-19 among children and adolescents. Randomized trials demonstrated that antibody responses to the mRNA vaccines in children six months and older are as high as (or higher than) those in older individuals [
         <a href="#rid83">
          83-88
         </a>
         ]. Efficacy data from these trials were limited, in part because of the low number of COVID-19 cases among study participants. However, subsequent observational studies suggest that vaccination is associated with reductions in COVID-19-related hospitalization, ICU admission, and death in adolescents, and reductions in hospitalization in younger school-aged children [
         <a href="#rid89">
          89-101
         </a>
         ]. As an example, in a meta-analysis of 17 studies that included over 11 million vaccinated and 2.5 million unvaccinated children between 5 and 11 years old, COVID-19 vaccination was associated with lower rates of COVID-19 associated hospitalization (OR 0.32) and MIS (OR 0.05) [
         <a href="#rid100">
          100
         </a>
         ]. Limited observational data suggest that vaccination is also associated with reductions in medically attended and severe infection among children younger than five years old [
         <a href="#rid102">
          102,103
         </a>
         ]. As in adults, vaccine effectiveness in children of all ages wanes over time [
         <a href="#rid98">
          98
         </a>
         ]. (See
         <a class="local">
          'Benefits of vaccination'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For children under five years old, assessment of vaccine efficacy is primarily extrapolated from studies demonstrating that the neutralizing activity elicited by vaccination is comparable with or higher than levels associated with protection in older populations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The individual benefit of COVID-19 vaccination in young children may be somewhat less than in adults because COVID-19 tends to be less severe in children than in adults. Nevertheless, the risk of the multisystem inflammatory syndrome in children (MIS-C) following acute infection, the potential for other sequelae of SARS-CoV-2 infection (eg, "long-COVID-19" and indirect effects on mental health and education), the risk of severe disease in children with underlying medical conditions, and the desire to prevent COVID-19 of any severity in children remain compelling reasons for their vaccination [
         <a href="#rid104">
          104
         </a>
         ]. Furthermore, even with the lower risk of severe disease among children, the number of COVID-19 deaths among those 6 months to 18 years old during the pandemic (even during 2022 when disease severity was lower) exceeded the prevaccination era mortality rates of infections for which childhood vaccines are routinely recommended (eg, rotavirus, meningococcal disease, varicella) [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risks and concerns in children
         </strong>
         – The safety profile of COVID-19 vaccines in children is similar to that in older individuals; mild local and systemic reactions are common but serious adverse events are rare. (See
         <a class="local">
          'Risks of vaccination'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The association of mRNA COVID-19 vaccines with myocarditis, particularly among male adolescents and young adults, has raised concern about this risk in younger children. However, data suggest that the risk is not higher than baseline [
         <a href="#rid106">
          106
         </a>
         ]. No cases of myocarditis thought related to vaccine were reported in the trials of the mRNA vaccines in young children [
         <a href="#rid107">
          107,108
         </a>
         ]. In a review of the Vaccine Adverse Event Reporting System (VAERS) following administration of approximately 8.7 million doses of
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Pfizer COVID-19 vaccine
         </a>
         to children aged 5 to 11 years in the United States, there were 11 verified reports of myocarditis in this age group [
         <a href="#rid109">
          109
         </a>
         ]; no cases were reported following 1.5 million doses among children six months to five years of age [
         <a href="#rid110">
          110
         </a>
         ]. As with other reported cases of mRNA COVID-19 vaccine-associated myocarditis, most cases were mild and of short duration. The benefits of COVID-19 vaccination in children are considered to exceed this risk [
         <a href="#rid111">
          111,112
         </a>
         ]. (See
         <a class="local">
          'Myocarditis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Given the hypothesis that MIS-C is associated with immune dysregulation precipitated by SARS-CoV-2 infection, similar immune-related side effects following vaccination in children were another concern. Vaccine trials in this age group have not identified a potential signal, although rare case reports of MIS in children and adults following vaccination highlight the importance of monitoring for this possible adverse effect [
         <a href="#rid113">
          113-115
         </a>
         ]. Nevertheless, evidence suggests that vaccination may protect against MIS-C [
         <a href="#rid116">
          116,117
         </a>
         ]. In a study of 102 patients aged 12 to 18 years hospitalized with MIS-C, 95 percent were unvaccinated; of the five patients with MIS-C who had previously received primary series of
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Pfizer COVID-19 vaccine
         </a>
         , none required invasive respiratory or cardiovascular support [
         <a href="#rid117">
          117
         </a>
         ]. The decision to vaccinate individuals with a history of MIS-C is discussed elsewhere. (See
         <a class="local">
          'History of SARS-CoV-2 infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         Most vaccines for children are delivered by private health care providers, although many are purchased using federal or other government funds. The Vaccines for Children (VFC) program is an entitlement program for all Advisory Committee on Immunization Practices (ACIP)-approved vaccines for eligible children through 18 years of age [
         <a href="#rid118">
          118,119
         </a>
         ]. Eligible children include those on Medicaid, those who are completely uninsured, and American Indian/Alaskan Natives. Approximately 50 percent of United States children are covered by the VFC. In addition, federal grants to states can be used to purchase vaccines to cover other children.
        </p>
        <p class="headingAnchor" id="H73856344">
         <span class="h2">
          Patient counseling
         </span>
        </p>
        <p class="headingAnchor" id="H1183162957">
         <span class="h3">
          Expected adverse effects and their management
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Common local and systemic reactions
         </strong>
         – Vaccine recipients should be advised that side effects are common and include local and systemic reactions, including pain at the injection site, ipsilateral axillary lymph node enlargement, fever, fatigue, and headache. Local and systemic side effects may reflect a robust immune response, as some studies suggest that recipients who report symptoms have slightly higher post-vaccination antibody levels than those who did not [
         <a href="#rid120">
          120,121
         </a>
         ]. Nevertheless, almost all immunocompetent recipients develop sufficiently high antibody levels, regardless of side effects. Among mRNA vaccines,
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Pfizer COVID-19 vaccine
         </a>
         may be associated with slightly lower rates of local and systemic reactions compared with mRNA-1273 [
         <a href="#rid122">
          122
         </a>
         ]. Rates of reactions for the distinct vaccines are discussed in detail elsewhere. (See
         <a class="local">
          'Common adverse effects'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although analgesics or antipyretics (eg, nonsteroidal anti-inflammatory drugs [NSAIDs] or
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         ) can be taken if these reactions develop, prophylactic use of such agents before vaccine receipt is not recommended because of the uncertain impact on the host immune response to vaccination [
         <a href="#rid26">
          26
         </a>
         ]. Although some data with other vaccines suggested a lower antibody response with prophylactic acetaminophen, the antibody responses to these vaccines remained in the protective range [
         <a href="#rid123">
          123,124
         </a>
         ].
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          Aspirin
         </a>
         is not recommended for individuals ≤18 years old because of the risk of Reye syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Syncope
         </strong>
         – Syncope has been reported following receipt of other injectable vaccines, particularly among adolescents and young adults [
         <a href="#rid125">
          125
         </a>
         ]. Monitoring individuals who have previously had syncope or may be at higher risk (eg, adolescents) for 15 minutes following COVID-19 vaccine receipt may help reduce the risk of syncope-related injury. (See
         <a class="local">
          'Monitoring for immediate reactions to vaccine'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rare adverse events
         </strong>
         – Very rare vaccine-associated adverse events include anaphylaxis and myocarditis with the mRNA vaccines. These issues and safety concerns with other COVID-19 vaccines are discussed in detail elsewhere. (See
         <a class="local">
          'Rare but serious associated events'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Uncommon skin reactions have also been reported following vaccination. These are also discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/127978.html" rel="external">
          "COVID-19: Cutaneous manifestations and issues related to dermatologic care", section on 'Considerations for vaccination to prevent SARS-CoV-2 infection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Other complications (including venous thromboembolic events without thrombocytopenia, deep vein thrombosis or pulmonary embolism, Bell palsy, and tinnitus) have been reported in vaccine recipients but have
         <strong>
          not
         </strong>
         been identified as causally related vaccine-associated adverse events. (See
         <a class="local">
          'Other reactions (without established association)'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3008159667">
         <span class="h3">
          Post-vaccine public health precautions
         </span>
         <span class="headingEndMark">
          —
         </span>
         SARS-CoV-2 infection might still occur despite vaccination. Recommendations on public health precautions following vaccination have evolved with new developments in the pandemic (eg, emergence of highly transmissible variants), and the approach should be tailored to the overall rate of transmission in the community. Recommendations on mask-wearing and postexposure management are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">
          "COVID-19: Epidemiology, virology, and prevention", section on 'Post-exposure management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2569996953">
         <span class="h2">
          Contraindications and precautions (including allergies)
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraindications
         </strong>
         – The following are the only contraindications to COVID-19 vaccination [
         <a href="#rid26">
          26
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A severe allergic reaction (eg, anaphylaxis) to a previous COVID-19 vaccine dose or to a component of the vaccine or a known (diagnosed) allergy to a component of the vaccine.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Symptoms of immediate reactions are listed on the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Fclinical-considerations%2Finterim-considerations-us-appendix.html&amp;token=JEHHJm%2FVE%2Fczu0Kvc1DVQUpygFBTbM3nx%2BQkzEPu166b1PdyYB%2FZy8UUx%2BhLrk1M6M7adxMuNRwuLsclowR%2BInMu5rgfG6pvkqGlpyWY%2BzeDWuJXy7rpwtTo6vB9J89C&amp;TOPIC_ID=129849" target="_blank">
          CDC website
         </a>
         . Isolated hives that develop more than four hours after vaccine receipt are unlikely to represent an allergic reaction to the vaccine and do not represent a contraindication to vaccine. (See
         <a class="medical medical_review" href="/z/d/html/132246.html" rel="external">
          "COVID-19: Allergic reactions to SARS-CoV-2 vaccines", section on 'Delayed-onset urticarial reactions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Precautions
         </strong>
         – Precautions to a specific COVID-19 vaccine include allergic reactions to other vaccines. Patients with such reactions can generally receive a COVID-19 vaccine but warrant longer post-vaccination monitoring than usual (see
         <a class="local">
          'Monitoring for immediate reactions to vaccine'
         </a>
         below):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Immediate allergic reaction to any other (non-COVID-19) vaccine or injectable therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prior immediate but nonsevere allergic reactions (eg, hives, angioedema that did not affect the airway) to a COVID-19 vaccine is a precaution (not contraindication) to that same vaccine type.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Allergy-related contraindication to one type of COVID-19 vaccine is a precaution to other types of COVID-19 vaccine because of potential cross-reactive hypersensitivity.
        </p>
        <p>
        </p>
        <p>
         The mRNA vaccines,
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Pfizer-BioNTech COVID-19 vaccine
         </a>
         and Moderna COVID-19 vaccine, each contain polyethylene glycol (PEG). However, it is a smaller molecular weight and less allergenic PEG than that present in other products, and multiple studies have documented safe receipt of the mRNA vaccines in individuals with known or suspected allergy to other PEG-containing products. The
         <a class="drug drug_general" data-topicid="135147" href="/z/d/drug information/135147.html" rel="external">
          Novavax COVID-19 vaccine
         </a>
         contains polysorbate, which is structurally related to PEG. Allergic reaction to polysorbate remains listed as a contraindication to Novavax COVID-19 vaccine and a precaution to mRNA vaccines. These issues are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/132246.html" rel="external">
          "COVID-19: Allergic reactions to SARS-CoV-2 vaccines", section on 'Uncertain role of polyethylene glycol'
         </a>
         .)
        </p>
        <p>
         Allergy consultation can be helpful to evaluate suspected allergic reactions to a COVID-19 vaccine or its components and assess the risk of future COVID-19 vaccination. Many individuals with apparent anaphylaxis after COVID-19 vaccination were able to receive a subsequent dose uneventfully after the reaction was determined not to be immunoglobulin E (IgE)-mediated. This is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/132246.html" rel="external">
          "COVID-19: Allergic reactions to SARS-CoV-2 vaccines", section on 'Possible anaphylaxis'
         </a>
         .)
        </p>
        <p>
         Caution is also warranted for those with a history of myocarditis or pericarditis following a COVID-19 vaccine, MIS-C, or Guillain-Barré syndrome (GBS). These issues are discussed elsewhere. (See
         <a class="local">
          'Myocarditis'
         </a>
         below and
         <a class="local">
          'History of SARS-CoV-2 infection'
         </a>
         above and
         <a class="local">
          'Guillain-Barré syndrome'
         </a>
         below.)
        </p>
        <p>
         Caution may be warranted prior to administering any vaccine in certain rare but life-threatening conditions, such as acquired thrombotic thrombocytopenic purpura and capillary leak syndrome, exacerbations of which have been reported following COVID-19 vaccination [
         <a href="#rid126">
          126,127
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/101762.html" rel="external">
          "Immune TTP: Management following recovery from an acute episode and during remission", section on 'Vaccinations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3919.html" rel="external">
          "Idiopathic systemic capillary leak syndrome", section on 'Prodromal symptoms and triggers'
         </a>
         .)
        </p>
        <p>
         History of thromboembolic disease is not a contraindication to vaccination with mRNA vaccines or
         <a class="drug drug_general" data-topicid="135147" href="/z/d/drug information/135147.html" rel="external">
          Novavax COVID-19 vaccine
         </a>
         . Although very rare cases of unusual types of thrombosis associated with thrombocytopenia have been reported following vaccination with certain adenoviral vector vaccines, there has not been a concerning signal for this type of thrombotic complication with mRNA COVID-19 vaccines. Furthermore, there is no evidence that classic risk factors for thrombosis (eg, thrombophilic disorders or prior history of venous thromboembolism not associated with thrombocytopenia) increase the risk for this rare adverse event [
         <a href="#rid128">
          128
         </a>
         ], and individuals with these can receive any approved or authorized COVID-19 vaccine. (See
         <a class="local">
          'Thrombosis with thrombocytopenia'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/131333.html" rel="external">
          "COVID-19: Vaccine-induced immune thrombotic thrombocytopenia (VITT)", section on 'Prevention (common questions)'
         </a>
         .)
        </p>
        <p>
         Other reactions or conditions that are neither precautions nor contraindications include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Late local reactions characterized by a well-demarcated area of erythema appearing at the injection site approximately one week after mRNA COVID-19 vaccination have been reported, with recurrence occurring in some individuals after repeat vaccination [
         <a href="#rid129">
          129
         </a>
         ]. This may occur more frequently with
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Moderna COVID-19 vaccine
         </a>
         than with Pfizer COVID-19 vaccine [
         <a href="#rid130">
          130
         </a>
         ]. This type of reaction is not a contraindication to vaccination, and individuals who experience this after the initial mRNA vaccine dose can proceed with the second dose as scheduled [
         <a href="#rid26">
          26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/132246.html" rel="external">
          "COVID-19: Allergic reactions to SARS-CoV-2 vaccines", section on 'Late local reactions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Facial swelling in areas previously injected with cosmetic dermal fillers has also been rarely reported following vaccination with the mRNA COVID-19 vaccines. Dermal fillers are not a contraindication to COVID-19 vaccination, and no specific precautions are recommended [
         <a href="#rid26">
          26
         </a>
         ]. However, it is reasonable to advise individuals with dermal fillers of the possibility of post-vaccination swelling. This is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/127978.html" rel="external">
          "COVID-19: Cutaneous manifestations and issues related to dermatologic care", section on 'Soft tissue fillers'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anticoagulation is not a contraindication to vaccination; excess bleeding is unlikely with intramuscular vaccines in patients taking anticoagulants [
         <a href="#rid131">
          131
         </a>
         ]. Such patients can be instructed to hold pressure over the injection site to reduce the risk of hematoma. (See
         <a class="medical medical_review" href="/z/d/html/3884.html" rel="external">
          "Standard immunizations for nonpregnant adults", section on 'Patients on anticoagulation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2030673777">
         <span class="h2">
          Monitoring for immediate reactions to vaccine
         </span>
         <span class="headingEndMark">
          —
         </span>
         All individuals should be monitored for immediate vaccine reactions following receipt of any COVID-19 vaccine.
        </p>
        <p>
         The following warrant monitoring for 30 minutes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Allergy-related contraindication to a different type of COVID-19 vaccine (see
         <a class="local">
          'Contraindications and precautions (including allergies)'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonsevere, immediate (onset within four hours) allergic reaction after a previous dose of COVID-19 vaccine
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of anaphylaxis after non-COVID-19 vaccines or injectable therapies
        </p>
        <p>
        </p>
        <p>
         Vaccines should be administered in settings where immediate allergic reactions, should they occur, can be appropriately managed. Recognition and management of anaphylaxis are discussed in detail elsewhere  (
         <a class="graphic graphic_table graphicRef58346" href="/z/d/graphic/58346.html" rel="external">
          table 6
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/106778.html" rel="external">
          "Anaphylaxis: Acute diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/392.html" rel="external">
          "Anaphylaxis: Emergency treatment"
         </a>
         and
         <a class="local">
          'Ongoing safety assessment and reporting of adverse events'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3779663500">
         <span class="h1">
          APPROACH TO VACCINATION IN OTHER COUNTRIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Various vaccines are available in different countries. A list of vaccines that have been authorized in at least one country can be found at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcovid19.trackvaccines.org%2Fvaccines%2F&amp;token=vJzeJSO96jlIEutymmylc0WAshtsX2AsUgsoIbJZAjXJrh7X9gNmTONJegAI3Bn9&amp;TOPIC_ID=129849" target="_blank">
          covid19.trackvaccines.org/vaccines
         </a>
         .
        </p>
        <p>
         Dosing schedules vary by vaccine. Additionally, different countries may have specific recommendations for vaccine use. Clinicians should refer to local guidelines for vaccine recommendations in their location. (See
         <a class="local">
          'Society guideline links'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2038692285">
         <span class="h1">
          BENEFITS OF VACCINATION
         </span>
        </p>
        <p class="headingAnchor" id="H1252311853">
         <span class="h2">
          Protection against severe disease or death
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vaccines available in the United States reduce the risk of severe or critical COVID-19 and have been associated with substantial reductions in COVID-19-associated hospitalizations and deaths [
         <a href="#rid17">
          17-24,132
         </a>
         ], even in the context of variants that partially evade vaccine-induced immune responses. Booster doses have been associated with restoration of vaccine effectiveness against severe infection that wanes over time. Hospitalization and mortality rates for COVID-19 have been consistently higher among unvaccinated compared with vaccinated individuals, particularly in those who received a vaccine dose within the several months preceding [
         <a href="#rid133">
          133
         </a>
         ]. In addition to direct reductions in COVID-19-associated morbidity and mortality, vaccination has been associated with lower non-COVID-19 mortality rates as well [
         <a href="#rid134">
          134
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk reduction compared with no vaccination
         </strong>
         – The large randomized trials evaluating the mRNA vaccines (the Pfizer COVID-19 vaccine and the
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Moderna COVID-19 vaccine
         </a>
         ) and the
         <a class="drug drug_general" data-topicid="135147" href="/z/d/drug information/135147.html" rel="external">
          Novavax COVID-19 vaccine
         </a>
         demonstrated 96 to 100 percent vaccine efficacy against severe infection; however, rates of severe infection in these trials were very low [
         <a href="#rid135">
          135-139
         </a>
         ]. Thus, most data demonstrating reductions in severe disease and death with vaccination are from large observational and population-based studies [
         <a href="#rid17">
          17-24,132
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As an example, in a study that evaluated over 8000 COVID-19-associated deaths in the United States between September 2022 and April 2023, receipt of vaccination, including a bivalent booster dose, was consistently associated with lower mortality compared with no vaccination; without vaccination, the risk of death was 7.3 to 16.3 times greater, depending on the prevalent Omicron sublineage [
         <a href="#rid138">
          138
         </a>
         ]. In another study of statewide data in North Carolina that included over 10 million adults, adjusted mRNA vaccine effectiveness at seven months following the primary series was 86 to 90 percent against hospitalization and 90 to 93 percent against death [
         <a href="#rid139">
          139
         </a>
         ]. At 12 months, the same measures were 60 to 65 percent and 70 to 75 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk
         </strong>
         <strong>
          of severe disease among vaccinated individuals
         </strong>
         – Among vaccinated individuals, the overall risk of severe COVID-19 is low [
         <a href="#rid140">
          140-144
         </a>
         ]. In a study of over one million vaccinated members of a large health system in the United States, the rates of severe disease and death due to breakthrough COVID-19 were 1.5 and 0.3 per 10,000, respectively [
         <a href="#rid144">
          144
         </a>
         ]. A history of vaccination has also been associated with lower rates of myocardial infarction, acute stroke, and other major adverse cardiovascular outcomes in patients with COVID-19 [
         <a href="#rid143">
          143,145
         </a>
         ]. Risk factors for severe COVID-19 after vaccination are similar to those for unvaccinated individuals: older age (&gt;65 years), immunocompromising conditions, and multiple comorbidities [
         <a href="#rid144">
          144,146
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impact of variants and time since vaccination (and effect of booster doses)
         </strong>
         – Vaccine effectiveness against severe disease wanes with time since the last vaccination, although the levels of protection against hospitalization and death are higher and sustained for longer than protection against symptomatic infection [
         <a href="#rid147">
          147-153
         </a>
         ]. Booster doses, both with monovalent and bivalent vaccines, have consistently been associated with greater protection against severe disease compared with more remote vaccination, although the effect of boosting also wanes over time [
         <a href="#rid139">
          139,154-167
         </a>
         ]. The pace and degree of waning following primary and booster vaccinations have varied across studies, however, and waning may be faster in the setting of Omicron compared with other variants [
         <a href="#rid168">
          168-177
         </a>
         ]. In a systematic review of observational studies evaluating protection against hospitalization after emergence of the Omicron variants, pooled vaccine effectiveness following a booster dose was 89 percent in the first month and 71 percent by four to six months [
         <a href="#rid178">
          178
         </a>
         ]. However, in another study of over 65,000 hospitalized adults during Omicron prevalence in the United States, vaccine effectiveness (which included a bivalent booster vaccine dose) against COVID-19-associated hospitalization compared with no vaccination waned from 62 percent during the first 60 days after the vaccine dose to 24 percent three to six months later [
         <a href="#rid179">
          179
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Decreases in observed vaccine effectiveness against severe disease may also be related to overall decreases in the risk of severe infection because of a higher prevalence of prior infection (which also provides protection against severe infection) as well as variants more associated with milder infection.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2026893440">
         <span class="h2">
          Protection against symptomatic infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the initial clinical trials reported extremely high efficacy rates with the Pfizer COVID-19 vaccine (90 to 100 percent [
         <a href="#rid83">
          83,84,135,180-182
         </a>
         ]), the
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Moderna COVID-19 vaccine
         </a>
         (86 to 100 percent [
         <a href="#rid107">
          107,136,183
         </a>
         ]), and the
         <a class="drug drug_general" data-topicid="135147" href="/z/d/drug information/135147.html" rel="external">
          Novavax COVID-19 vaccine
         </a>
         (80 to 90 percent [
         <a href="#rid137">
          137,184,185
         </a>
         ]) in preventing laboratory-confirmed symptomatic infection within the first two months of infection, their observed effectiveness against infection has decreased over time because of waning immunity and immune evasion by certain circulating SARS-CoV-2 variants.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impact of variants and time since vaccination (and effect of booster doses)
         </strong>
         – Multiple observational studies have consistently suggested that vaccine protection against symptomatic infection is lower with Omicron compared with other variants and wanes over time (after both primary series and booster vaccinations and with both monovalent and bivalent vaccines) in children and adults [
         <a href="#rid186">
          186-198
         </a>
         ]. In a systematic review of 40 studies evaluating vaccine effectiveness since the emergence of the Omicron variant, pooled estimates for vaccine efficacy against symptomatic disease decreased from 53 to 14 percent at one and six months after completing the primary vaccine series; a booster dose was associated with restoration of effectiveness, although this also waned to &lt;20 percent after nine months [
         <a href="#rid197">
          197
         </a>
         ]. The estimated half-life of vaccine effectiveness was 111 days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The relative effects of booster doses to temporarily restore vaccine effectiveness against infection are greater in the few months following the booster dose and if more time has elapsed since the prior vaccine dose [
         <a href="#rid89">
          89,157,159,162,164,166,199-205
         </a>
         ]. As an example, in a study in the United States of over 250,000 symptomatic individuals who were tested for SARS-CoV-2 and had received two to four doses of monovalent vaccines, vaccine effectiveness of an additional booster dose (with a bivalent vaccine) against symptomatic COVID-19 was greater if more time had elapsed between the last vaccine dose and the additional booster (28 to 31 percent if the interval was two to three months versus 43 to 56 percent if it was more than eight months) [
         <a href="#rid199">
          199
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Updating a vaccine to better match the antigenic target with circulating variants is presumed to be associated with a boost in effectiveness against symptomatic infection, although this is likely short-lived as well. (See
         <a class="local">
          'Antibody responses and immune correlates of protection'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impact on character and duration of breakthrough infection (including risk of long-COVID-19)
         </strong>
         – Multiple observational studies suggest that breakthrough infection in vaccinated individuals is associated with fewer and shorter duration of symptoms, a lower likelihood of "long COVID-19" (otherwise unexplained symptoms that persist at least two to three months after infection), and a higher likelihood of asymptomatic infection compared with infection in unvaccinated individuals [
         <a href="#rid206">
          206-209
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1606921902">
         <span class="h2">
          Impact on transmission risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         Widespread vaccination reduces the overall transmission risk since vaccinated individuals are less likely to become infected. Data accumulated prior to the emergence of the Omicron variant also suggested that individuals who developed infection despite vaccination may be less likely to transmit to others [
         <a href="#rid210">
          210-215
         </a>
         ].
        </p>
        <p>
         Vaccination may also reduce the likelihood of transmission in the setting of Omicron infection [
         <a href="#rid216">
          216-218
         </a>
         ]. In a study of individuals in a state prison system in the United States conducted when BA.1 and BA.2 Omicron subvariants were dominant, the overall secondary attack rate from 1126 index SARS-CoV-2 cases to their cellmates was 30 percent [
         <a href="#rid216">
          216
         </a>
         ]. The risk of transmission from index cases who had been vaccinated was compared with index cases who had neither vaccination nor previous infection (22 percent lower in those with vaccination without prior infection and 40 percent lower in those with both vaccination and prior infection). The risk of transmission from vaccinated individuals was lower following booster vaccination than primary series alone. Prior infection alone was also associated with a lower transmission risk.
        </p>
        <p class="headingAnchor" id="H2634827862">
         <span class="h2">
          Comparative efficacy between vaccine types
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although precise comparative efficacy is uncertain because the different vaccines have not been compared head to head in clinical trials, limited evidence from observational studies suggests that
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Moderna COVID-19 vaccine
         </a>
         may be slightly more effective than Pfizer COVID-19 vaccine [
         <a href="#rid219">
          219-226
         </a>
         ]. However, it is unclear whether the difference is clinically significant. As an example, in a study from the United States that compared over 400,000 veterans who received one of the two mRNA vaccines, Moderna COVID-19 vaccine was associated with lower rates of documented infection, symptomatic COVID-19, and associated hospitalization over 24 weeks, but the absolute differences were low (differences of 1.23, 0.44, and 0.55 cases per 1000 people, respectively) [
         <a href="#rid221">
          221
         </a>
         ]. Safety of the mRNA vaccines in the same cohort was largely comparable, with only small differences in serious adverse events of uncertain clinical significance [
         <a href="#rid227">
          227
         </a>
         ].
        </p>
        <p>
         Because it has not been available for as long as the other vaccines, data on
         <a class="drug drug_general" data-topicid="135147" href="/z/d/drug information/135147.html" rel="external">
          Novavax COVID-19 vaccine
         </a>
         are more limited, although large, randomized trials support its safety and efficacy.
        </p>
        <p class="headingAnchor" id="H4134342368">
         <span class="h2">
          Antibody responses and immune correlates of protection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although data remain limited, analyses of vaccine trials support the concept that binding and neutralizing antibody levels against the spike protein and its receptor-binding domain are the primary immune predictors of protection against symptomatic infection, with increasing levels associated with progressively higher vaccine efficacy [
         <a href="#rid228">
          228,229
         </a>
         ]. Data from these studies can help assess likely efficacy of new vaccines or formulations (eg, with new antigenic targets) in different patient populations when large efficacy trials cannot be performed. However, the application to clinical care is uncertain; it is unknown how well results from the various commercially available serologic tests correspond to the measurement of antibody levels in the clinical trials. Furthermore, the immune correlates of protection against severe infection have not been fully elucidated. Vaccine- or infection-induced cellular immunity often appears robust against variants that escape antibody binding, and this may contribute to the reduced risk of severe disease from such variants [
         <a href="#rid230">
          230-233
         </a>
         ].
        </p>
        <p>
         Using COVID-19 vaccines with altered spike targets to more closely match circulating SARS-CoV-2 variants is analogous to updating the seasonal influenza vaccine each year; influenza vaccines are made available globally based on immunogenicity studies prior to repeated clinical evaluation because of extensive experience with the preceding versions.
        </p>
        <p>
         In human and animal immunogenicity studies, the 2023-2024 formula COVID-19 vaccines that are based on the spike protein of the XBB.1.5 variant elicited robust neutralizing antibody levels against related Omicron variants that are prevalent in the fall of 2023 (eg, EG.5.1, FL.1.5.1, XBB.1.16) as well as the Omicron variant BA.2.86, which had raised concern for having the potential to escape immunity from other variants [
         <a href="#rid234">
          234-236
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2533983946">
         <span class="h1">
          RISKS OF VACCINATION
         </span>
        </p>
        <p class="headingAnchor" id="H448600461">
         <span class="h2">
          Common adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Local and systemic adverse effects are relatively common with the mRNA vaccines (Pfizer COVID-19 vaccine and
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Moderna COVID-19 vaccine
         </a>
         ) and the recombinant
         <a class="drug drug_general" data-topicid="135147" href="/z/d/drug information/135147.html" rel="external">
          Novavax COVID-19 vaccine
         </a>
         . Most are of mild or moderate severity (ie, do not prevent daily activities or require pain relievers) and are limited to the first two to three days after vaccination [
         <a href="#rid122">
          122,237,238
         </a>
         ]. Approximately 10 to 20 percent of recipients have adverse effects that limit school attendance or daily life activities [
         <a href="#rid239">
          239,240
         </a>
         ].
        </p>
        <p>
         Common injection site reactions include mainly pain, as well as redness, swelling, and pruritus. Among the mRNA vaccines, slightly higher rates have been reported for the
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Moderna COVID-19 vaccine
         </a>
         (in 75 to 80 percent) than for the Pfizer COVID-19 vaccine (65 percent) [
         <a href="#rid122">
          122
         </a>
         ].
        </p>
        <p>
         Similarly, reported rates of nonsevere systemic adverse effects, such as fatigue, headache, and myalgia (50 to 60 versus 40 to 50 percent), and fevers, chills, and joint pain (30 to 40 versus 20 percent) appear slightly higher with
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Moderna COVID-19 vaccine
         </a>
         than Pfizer COVID-19 vaccine [
         <a href="#rid122">
          122
         </a>
         ].
        </p>
        <p>
         In general, the rates of common reactions are lower among older (eg, &gt;65 years) compared with younger adults and are lower among younger children than adolescents [
         <a href="#rid83">
          83,182
         </a>
         ]. Among young children, irritability, crying, drowsiness, and loss of appetite are common; febrile seizures are rare [
         <a href="#rid107">
          107,108
         </a>
         ].
        </p>
        <p>
         Review of active and passive surveillance systems in the United States suggests that the safety profile of the bivalent mRNA vaccines was similar to that of the monovalent mRNA vaccines in children and adults [
         <a href="#rid239">
          239,240
         </a>
         ]. Local injection reactions, headache, myalgia, and fever are the most common side effects and are short lived, although they limit school attendance or daily life activities in 10 to 20 percent of recipients.
        </p>
        <p class="headingAnchor" id="H2650237379">
         <span class="h2">
          Rare but serious associated events
         </span>
         <span class="headingEndMark">
          —
         </span>
         COVID-19 vaccines are exceedingly safe. The primary safety concerns are a very rare risk of myocarditis with mRNA vaccines and possibly recombinant protein vaccines and very rare risks of thrombosis with thrombocytopenia and Guillain-Barré syndrome (GBS) with adenoviral vector vaccines (which are not used in the United States). Active and passive surveillance systems in adults and children have failed to find other clear associations with major adverse events [
         <a href="#rid241">
          241
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2581314898">
         <span class="h3">
          Myocarditis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Myocarditis and pericarditis, mainly in male adolescents and young adults, have been reported more frequently than expected following receipt of the mRNA vaccines, Pfizer COVID-19 vaccine and
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Moderna COVID-19 vaccine
         </a>
         [
         <a href="#rid242">
          242,243
         </a>
         ]. Cases were also noted in
         <a class="drug drug_general" data-topicid="135147" href="/z/d/drug information/135147.html" rel="external">
          Novavax COVID-19 vaccine
         </a>
         recipients during the phase III trials [
         <a href="#rid244">
          244
         </a>
         ], and surveillance suggested a possible increased risk following receipt of
         <a class="drug drug_general" data-topicid="130461" href="/z/d/drug information/130461.html" rel="external">
          Janssen/Johnson &amp; Johnson COVID-19 vaccine
         </a>
         , which is no longer used in the United States [
         <a href="#rid16">
          16
         </a>
         ]. Given the infrequency and the typically mild nature of the myocarditis and pericarditis cases, the benefits of vaccination greatly exceed the small increased risk [
         <a href="#rid243">
          243
         </a>
         ].
        </p>
        <p>
         For those who develop myocarditis or pericarditis following an mRNA vaccine or
         <a class="drug drug_general" data-topicid="135147" href="/z/d/drug information/135147.html" rel="external">
          Novavax COVID-19 vaccine
         </a>
         , we suggest that any subsequent COVID-19 vaccine dose be deferred in most cases; it is reasonable for such individuals to choose to receive an additional dose (ie, the second dose of the primary series or any booster doses) once the episode has completely resolved if the risk of severe COVID-19 is high [
         <a href="#rid26">
          26
         </a>
         ]. Individuals with a history of resolved myocarditis or pericarditis unrelated to COVID-19 vaccination can receive a COVID-19 vaccine.
        </p>
        <p>
         In a review of the Vaccine Adverse Event Reporting System (VAERS), a passive surveillance system in the United States to which patients and providers can submit reports of events, among over 192 million people who had received an mRNA vaccine between December 2020 and August 2021, there were 1626 cases that met the definition of myocarditis following vaccine receipt [
         <a href="#rid245">
          245
         </a>
         ]. The majority of these cases occurred after the second dose, the median age was 21 years, and 82 percent occurred in males. The estimated rate among males by age group was:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         12 to 15 years old – 70.7 cases per million doses of
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Pfizer COVID-19 vaccine
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         16 to 17 years old – 105.9 cases per million doses of
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Pfizer COVID-19 vaccine
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         18 to 24 years old – 52.4 to 56.3 cases per million doses Pfizer COVID-19 vaccine and
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Moderna COVID-19 vaccine
         </a>
         , respectively
        </p>
        <p>
        </p>
        <p>
         Among females of the same age groups, the estimated case rates ranged from 6.4 to 11 cases per million doses. The number of events observed exceeded the expected baseline rate among males aged 18 to 49 years and females aged 19 to 29 years.
        </p>
        <p>
         Estimated rates of myocarditis from the Vaccine Safety Datalink (VSD), an active surveillance system in the United States, which recorded a total of 320 cases of myocarditis following seven million vaccine doses, were somewhat higher, possibly because the system does not rely on the patients or providers to make special efforts to report cases [
         <a href="#rid246">
          246
         </a>
         ]. Among males, the estimated rates of myocarditis within the week following a second vaccine dose were 150.5 cases (ages 12 to 15 years), 127.1 (ages 16 to 17 years), and 81.4 (ages 18 to 29 years) per million doses of BNT162b2 and 97.0 (ages 18 to 29 years) per million doses of mRNA-1273.
        </p>
        <p>
         Studies from other countries have also suggested an increased rate of myocarditis following Pfizer COVID-19 vaccine receipt compared with the expected background rate [
         <a href="#rid100">
          100,247-251
         </a>
         ]. Observational data also suggest that the risk may be higher with
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Moderna COVID-19 vaccine
         </a>
         than Pfizer COVID-19 vaccine [
         <a href="#rid252">
          252-255
         </a>
         ]. The risk also appears to be higher following the second dose and with shorter intervals between doses (eg, less than 30 versus more than 60 days) [
         <a href="#rid256">
          256
         </a>
         ].
        </p>
        <p>
         For all age groups, the risk of myocarditis or pericarditis following mRNA vaccination is estimated in some, but not all [
         <a href="#rid254">
          254
         </a>
         ], studies to be less than the risk associated with SARS-CoV-2 infection [
         <a href="#rid257">
          257
         </a>
         ].
        </p>
        <p>
         Among the cases that have been reported, most are mild [
         <a href="#rid243">
          243,247,248,258,259
         </a>
         ]. Onset was generally within the first week after vaccine receipt. Most patients who presented for care responded well to medical treatment and had rapid symptom improvement. There have been very rare reports of persistent or fulminant myocarditis in individuals who had received an mRNA vaccine within the preceding weeks [
         <a href="#rid260">
          260,261
         </a>
         ]. Although a study from Korea reported that 20 percent of the 480 cases of vaccine-associated myocarditis identified nationwide were severe, with 36 fulminant cases and 21 deaths, that report is an outlier compared with those from other countries [
         <a href="#rid262">
          262
         </a>
         ].
        </p>
        <p>
         The typical clinical presentation was illustrated in a retrospective study of 139 adolescents and young adults ≤21 years old with suspected vaccine-associated myocarditis based on elevated troponins within 30 days of vaccination without alternative diagnosis [
         <a href="#rid263">
          263
         </a>
         ]. Almost all presented with chest pain, with symptom onset a median of two days after vaccine receipt, which was often receipt of the second vaccine dose. Electrocardiogram was abnormal in 70 percent (ST-segment elevations or T-wave abnormalities), cardiac magnetic resonance imaging (MRI) was abnormal in 77 percent (late gadolinium enhancement and myocardial edema), but systolic function on echocardiogram was normal in 80 percent. Nineteen percent were managed in the intensive care unit (ICU), although only two patients required inotropic or vasopressor support. Median hospital stay was two days, and those with decreased systolic function had normalized ejection fraction on follow-up. Ongoing monitoring is necessary to assess for long-term sequelae.
        </p>
        <p>
         The possibility of myocarditis should be considered in adolescents and young adults who develop new chest pain, shortness of breath, or palpitations after receiving an mRNA vaccine. The possibility of other causes of myocarditis (including SARS-CoV-2 infection) should also be considered. The diagnosis and management of myocarditis are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5755.html" rel="external">
          "Clinical manifestations and diagnosis of myocarditis in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4939.html" rel="external">
          "Clinical manifestations and diagnosis of myocarditis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5761.html" rel="external">
          "Treatment and prognosis of myocarditis in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4935.html" rel="external">
          "Treatment and prognosis of myocarditis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2191022625">
         <span class="h3">
          Events associated with vaccines not used in the United States
         </span>
        </p>
        <p class="headingAnchor" id="H3316360804">
         <span class="h4">
          Thrombosis with thrombocytopenia
         </span>
         <span class="headingEndMark">
          —
         </span>
         ChadOx1 nCoV-19/AZD1222 (AstraZeneca COVID-19 vaccine) and Ad26.COV2.S (
         <a class="drug drug_general" data-topicid="130461" href="/z/d/drug information/130461.html" rel="external">
          Janssen COVID-19 vaccine
         </a>
         , also referred to as the Johnson &amp; Johnson vaccine) have each been associated with an extremely small risk of unusual types of thrombotic events associated with thrombocytopenia. A similar risk has not been identified with the mRNA vaccines. Many of these cases have been associated with autoantibodies directed against the platelet factor 4 (PF4) antigen, similar to those found in patients with autoimmune heparin-induced thrombocytopenia (HIT) [
         <a href="#rid264">
          264-267
         </a>
         ]. Some experts refer to this syndrome as vaccine-associated immune thrombotic thrombocytopenia (VITT); others have used the term thrombosis with thrombocytopenia syndrome (TTS). Neither of these vaccines is used in the United States.
        </p>
        <p>
         In reported cases, thrombosis often occurred at unusual sites, including the cerebral venous sinuses and mesenteric vessels, and at more than one site [
         <a href="#rid268">
          268-270
         </a>
         ]. Most of the initially reported events occurred within two weeks of receipt of the initial vaccine dose and in females under 60 years of age, although subsequent cases have been reported following a longer post-vaccine interval and in males and older females. Some fatal cases have been reported.
        </p>
        <p>
         In the United States, the risks of this syndrome following Ad26.COV2.S receipt was assessed as 3.8 cases and 0.57 deaths per million doses overall, and 9 to 10.6 cases and 1.8 to 1.93 deaths per million doses for females 30 to 49 years old [
         <a href="#rid271">
          271
         </a>
         ]. Regulatory bodies in the United States and Europe have concluded that the population and individual benefits of these vaccines (compared with no vaccination), including reductions in death and critical illness, outweigh the risk of these rare events [
         <a href="#rid272">
          272-274
         </a>
         ]. Additionally, the risk of hospitalization or death associated with thrombocytopenia or thromboembolic complications associated with SARS-CoV-2 infection is higher than that associated with adenoviral vaccines [
         <a href="#rid275">
          275
         </a>
         ]. Nevertheless, recipients of these vaccines should be aware of the possible association and seek immediate care for signs and symptoms suggestive of thrombocytopenia (eg, new petechiae or bruising) or thrombotic complications (including shortness of breath, chest pain, lower extremity edema, persistent severe abdominal pain, unabating severe headache, severe backache, new focal neurologic symptoms, and seizures) [
         <a href="#rid274">
          274
         </a>
         ].
        </p>
        <p>
         The incidence, risk factors, clinical features, evaluation, and management of VITT/TTS are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/131333.html" rel="external">
          "COVID-19: Vaccine-induced immune thrombotic thrombocytopenia (VITT)"
         </a>
         .)
        </p>
        <p>
         A clear, causal relation between either of these vaccines and thromboembolic disorders overall (eg, pulmonary embolism and deep vein thrombosis) has not been identified [
         <a href="#rid276">
          276,277
         </a>
         ]. For ChadOx1 nCoV-19/AZD1222, studies have reported conflicting findings regarding this risk.
        </p>
        <p class="headingAnchor" id="H3742812494">
         <span class="h4">
          Guillain-Barré syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         The adenovirus vector vaccines (Ad26.COV2.S [
         <a class="drug drug_general" data-topicid="130461" href="/z/d/drug information/130461.html" rel="external">
          Janssen/Johnson &amp; Johnson COVID-19 vaccine
         </a>
         ] and ChAdOx1 nCoV-19/AZD1222 [AstraZeneca COVID-19 vaccine]) have been associated with GBS. A similar signal has not been observed with the mRNA COVID-19 vaccines. The US Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) and European regulators affirm that the benefits of these vaccines outweigh their risks [
         <a href="#rid278">
          278,279
         </a>
         ]. Cases of GBS, including recurrent cases, have also been reported in the setting of SARS-CoV-2 infection [
         <a href="#rid280">
          280,281
         </a>
         ], and observational data suggest the risk of GBS after infection exceeds the risk after vaccination [
         <a href="#rid282">
          282
         </a>
         ]. Pending additional data, for individuals with a documented history of GBS, we suggest using COVID-19 vaccines other than adenovirus vector vaccines (adenovirus vector vaccines are not available in the United States). The general approach to vaccination in individuals with a history of GBS is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5172.html" rel="external">
          "Guillain-Barré syndrome in adults: Treatment and prognosis", section on 'Subsequent immunizations'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ad26.COV2.S
         </strong>
         – When Ad26.COV2.S was available in the United States, studies of different surveillance systems suggested a higher incidence of GBS following that vaccine compared with others [
         <a href="#rid283">
          283-285
         </a>
         ]. In an evaluation of almost 500 million COVID-19 vaccine doses administered in the United States, 295 verified cases of GBS were reported to a passive surveillance system [
         <a href="#rid285">
          285
         </a>
         ]. The rate of GBS reported within 212 days after vaccination was higher for Ad26.COV2.S than for BNT162b2 or mRNA-1273 (3.29 cases compared with 0.29 and 0.35 cases per million doses). The number of cases observed after Ad26.COV2.S was 3.8 times the expected rate in the general population. The median age was 59 years (interquartile range [IQR] 46 to 68), and the median time from Ad26.COV2.S receipt and GBS was 10 days (IQR 5 to 17). Two deaths occurred in individuals with GBS reported after Ad26.COV2.S. In an earlier report of 100 cases, a quarter of the patients reported bilateral facial weakness [
         <a href="#rid286">
          286
         </a>
         ]. This vaccine is no longer available in the United States.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ChAdOx1 nCoV-19/AZD1222
         </strong>
         – Reviews of surveillance systems in Europe and the United Kingdom have suggested an excess number of GBS cases following ChAdOx1 nCoV-19/AZD1222 vaccination (an excess of 0.58 cases per 100,000 doses according to one analysis) [
         <a href="#rid279">
          279,287
         </a>
         ]. Other scattered reports have also described GBS, including variant GBS with bilateral facial weakness, following ChAdOx1 nCoV-19/AZD1222 vaccination [
         <a href="#rid288">
          288,289
         </a>
         ]. However, in a cohort study including over four million individuals who received ChAdOx1 nCoV-19/AZD1222, the rate of GBS following the vaccine dose was not higher than the expected prepandemic background rate [
         <a href="#rid290">
          290
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4108291142">
         <span class="h2">
          Other reactions (without established association)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although myriad adverse events have been reported in individuals following vaccine administration, no other severe events than those listed above have been clearly associated with vaccination after hundreds of millions of doses administered.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          No clear signal of ischemic stroke with the bivalent mRNA vaccines
         </strong>
         – One active surveillance system (the VSD) reported a slightly higher-than-expected number of ischemic strokes in individuals ≥65 years of age following receipt of the bivalent
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Pfizer-BioNTech COVID-19 vaccine
         </a>
         ; however, the rate excess decreased with time and there was no increased incidence of other cardiovascular events [
         <a href="#rid291">
          291,292
         </a>
         ]. Furthermore, additional analyses did not identify a similar signal in several other surveillance systems or with the bivalent Moderna COVID-19 vaccine [
         <a href="#rid291">
          291,293-296
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Possible anaphylaxis
         </strong>
         – Anaphylaxis has been reported following administration of both mRNA COVID-19 vaccines [
         <a href="#rid297">
          297
         </a>
         ]. Following the first several million doses of mRNA COVID-19 vaccines administered in the United States, anaphylaxis was reported at approximate rates of 4.5 events per million doses [
         <a href="#rid237">
          237,298,299
         </a>
         ]; rates ranging from 2.5 to 7.9 events per million doses have been reported, depending on the surveillance system [
         <a href="#rid300">
          300-302
         </a>
         ]. The vast majority of these events occurred in individuals with a history of prior allergic reactions and occurred within 30 minutes. However, many of those who had a reaction after the first vaccination did not suffer a similar reaction after the second dose. Data suggest that the majority are not IgE-mediated reactions [
         <a href="#rid303">
          303
         </a>
         ] and complement-mediated mechanisms have not been documented. Some cases have been reported as stress-related events [
         <a href="#rid304">
          304,305
         </a>
         ]. Possible anaphylaxis and other reported allergic reactions (eg, pruritus, rash, scratchy sensations in the throat, and mild respiratory symptoms) are discussed elsewhere [
         <a href="#rid306">
          306
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/132246.html" rel="external">
          "COVID-19: Allergic reactions to SARS-CoV-2 vaccines", section on 'mRNA vaccines'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          No clear impact on fertility
         </strong>
         – As an example, many patients of child-bearing potential are concerned that COVID-19 vaccination could adversely impact fertility. However, in epidemiologic studies, there is no association between COVID-19 vaccination and fertility problems in either females or males [
         <a href="#rid307">
          307,308
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Other major adverse events have also not been consistently associated with mRNA or recombinant protein vaccines. Rare cases of Bell palsy were noted in the trials for both Pfizer COVID-19 vaccine and
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Moderna COVID-19 vaccine
         </a>
         , although the rate did not exceed background rates found in the general population (15 to 30 cases per 100,000 people per year), and post-vaccine monitoring has not identified an association between vaccination and Bell palsy [
         <a href="#rid298">
          298,300
         </a>
         ]. No other major vaccine-associated adverse events have been clearly identified in post-vaccine surveillance [
         <a href="#rid300">
          300
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2957895988">
         <span class="h2">
          Ongoing safety assessment and reporting of adverse events
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adequately assessing vaccine safety is critical to the success of immunization programs. Although existing comprehensive systems to monitor vaccine safety are in place, they were enhanced for the rollout of the COVID-19 vaccine program. It is particularly important to identify rare adverse events that are causally related to vaccine administration and assess their incidence and risk factors to inform potential vaccine contraindications.
        </p>
        <p>
         In the United States, there are several systems in place to assess safety in the post-licensure setting; some are passive (ie, rely on others reporting the event) and others are active (ie, review databases or conduct studies to identify events) [
         <a href="#rid309">
          309
         </a>
         ]. These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vaccine Adverse Event Reporting System
         </strong>
         – this is a passive surveillance system in which providers, parents, and patients report adverse events. VAERS is intended to raise hypotheses about whether receipt of a vaccine could cause the adverse event rather than evaluate causation. To facilitate ongoing safety evaluation, vaccine providers are responsible for reporting vaccine administration errors, serious adverse events associated with vaccination, cases of multisystem inflammatory syndrome (MIS), and cases of COVID-19 that result in hospitalization or death through VAERS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vaccine Safety Datalink
         </strong>
         – this is a collaborative project between the CDC's Immunization Safety Office and eight health care organizations to actively monitor the safety of vaccines and conduct studies about rare and serious post-vaccination adverse events. Analysis of the VSD can help determine if adverse events are causally or only coincidentally related to vaccination by comparing the incidence of given clinical syndrome in vaccinees at time points soon after vaccination with time points before or well after vaccination [
         <a href="#rid300">
          300
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical Immunization Safety Assessment project (CISA)
         </strong>
         – this is a national network of vaccine safety experts from the CDC's Immunization Safety Office, seven academic medical research centers, and subject matter experts, and it provides a comprehensive vaccine safety public health service to the nation.
        </p>
        <p>
        </p>
        <p>
         In addition, specific post-licensure vaccine safety systems have been implemented for the introduction of COVID-19 vaccines, similar to those established during the 2009 H1N1 influenza pandemic [
         <a href="#rid310">
          310,311
         </a>
         ]. These systems have been coordinated through the CDC and have enlisted multiple other health care groups to provide ongoing data on vaccine safety. These systems and information sources add an additional layer of safety monitoring [
         <a href="#rid312">
          312,313
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Enhanced reporting through National Healthcare Safety Network (NHSN) sites
         </strong>
         – A monitoring system for health care workers and long-term care facility residents that reports to the VAERS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring of larger insurer/payer databases through the FDA
         </strong>
         – A system of administrative and claims-based data for surveillance and research.
        </p>
        <p>
        </p>
        <p>
         Since most vaccine-preventable diseases are transmitted person-to-person, effective vaccination not only protects the recipient but also indirectly protects others who cannot be vaccinated or do not respond adequately by preventing another source for transmission ("herd immunity") [
         <a href="#rid314">
          314
         </a>
         ]. Therefore, if someone is injured by vaccine, society owes that person compensation. This is the basis for the National Vaccine Injury Compensation Program (NVICP) [
         <a href="#rid315">
          315
         </a>
         ]. This program also reduces liability for the vaccine provider and the manufacturer, since it is a no-fault alternative to the traditional legal system for resolving vaccine injury claims. With COVID-19 vaccines, another compensation system called the Countermeasures Injury Compensation Program (CICP) may be used [
         <a href="#rid316">
          316
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2609763923">
         <span class="h1">
          COMBATING VACCINE HESITANCY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vaccine hesitancy presents a major obstacle to achieving broad vaccination coverage. In general, vaccine hesitancy has become more common worldwide and was cited by the World Health Organization (WHO) as a top 10 global health threat in 2019 [
         <a href="#rid317">
          317
         </a>
         ]. With COVID-19 vaccines, the accelerated nature of development and misinformation have further contributed to concerns or skepticism about safety and utility among vaccine-hesitant individuals. Efforts to optimize COVID-19 vaccine uptake should identify reasons for and characteristics associated with vaccine refusal and use that information to tailor approaches to individuals and populations.
        </p>
        <p>
         Based on evidence from other vaccines, health care providers can improve vaccine acceptance in individual patients by making direct recommendations for vaccination, identifying concerns, educating patients on vaccine risks and benefits, and dispelling misconceptions about the disease and the vaccine. (See
         <a class="medical medical_review" href="/z/d/html/2846.html" rel="external">
          "Standard childhood vaccines: Caregiver hesitancy or refusal", section on 'Target education'
         </a>
         .)
        </p>
        <p>
         Communication points that may be helpful when speaking with patients who are uncertain about whether to receive a COVID-19 vaccine can be found
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.vitaltalk.org%2Fwp-content%2Fuploads%2FCommunication-skills-for-the-COVID-vaccine_v1.2-1.pdf&amp;token=G1MqHbY0kglEZBkvftdb%2BtU7Gu58HJZDxbdR3M36Ti6Oc%2FNVp8A%2B8pFmXs7hK%2BgvYDMmzb2bJpVAsJ2sAgv5Rkysav%2FOb%2FBBlRbvaOWEOL8MGWtMYTbgq6g5wIc5IWPS&amp;TOPIC_ID=129849" target="_blank">
          here
         </a>
         or on the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Fhcp%2Fengaging-patients.html&amp;token=YaohCNbz%2FPCe85wXw4gcv%2F2BNHwoKDlUucRuSe2aUK%2BrnmzVHnF6z%2BSjr8pfNpX%2F3v3kP4fRcf%2ByKapyrfBV3uv6zlMfB7gs%2FW%2FV9UbRnU8%3D&amp;TOPIC_ID=129849" target="_blank">
          Centers for Disease Control and Prevention (CDC) website
         </a>
         [
         <a href="#rid318">
          318,319
         </a>
         ].
        </p>
        <p>
         Willingness to accept a COVID-19 vaccine has varied by country [
         <a href="#rid320">
          320,321
         </a>
         ]. In the United States, rates of vaccine hesitancy have decreased over the course of the pandemic but remain substantial [
         <a href="#rid322">
          322-325
         </a>
         ]. COVID-19 vaccine hesitancy has been associated with younger age (eg, &lt;60 years old), lower levels of education, lower household income, rural residence, and lack of health insurance [
         <a href="#rid322">
          322,326-328
         </a>
         ]. In a CDC survey, the main reasons for reporting nonintent to receive vaccine were concerns about vaccine side effects and safety and lack of trust in the process [
         <a href="#rid326">
          326
         </a>
         ]. Vaccination rates in the United States increase with age; rates among children have been especially low. As of April 2023, fewer than 35 percent of children 5 to 11 years had received a primary vaccine series and fewer than 5 percent had received a bivalent vaccine dose; rates among younger children were much lower [
         <a href="#rid329">
          329
         </a>
         ].
        </p>
        <p>
         Among individuals who have received a primary COVID-19 vaccine series, major reasons for not receiving a booster dose are lack of awareness about eligibility or availability, belief that they remain protected against severe infection without it, and uncertainty about the vaccine safety and efficacy [
         <a href="#rid330">
          330
         </a>
         ]. These findings highlight the role for clinicians in educating patients on emerging vaccine data and recommendations.
        </p>
        <p class="headingAnchor" id="H4270317435">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/126613.html" rel="external">
          "Society guideline links: COVID-19 – Index of guideline topics"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3495744393">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/130329.html" rel="external">
          "Patient education: COVID-19 vaccines (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/126678.html" rel="external">
          "Patient education: COVID-19 overview (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/127758.html" rel="external">
          "Patient education: COVID-19 and pregnancy (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/127544.html" rel="external">
          "Patient education: COVID-19 and children (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2498750472">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antigenic target
         </strong>
         – The primary antigenic target for COVID-19 vaccines is the large surface spike protein  (
         <a class="graphic graphic_figure graphicRef130132" href="/z/d/graphic/130132.html" rel="external">
          figure 1
         </a>
         ), which binds to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells  (
         <a class="graphic graphic_figure graphicRef130134" href="/z/d/graphic/130134.html" rel="external">
          figure 2
         </a>
         ). Over time, the mRNA vaccines have been reformulated to target the mutations in the spike proteins of various SARS-CoV-2 variants. As of September 2023, COVID-19 vaccines are only available as updated 2023-2024 formulations (
         <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">
          Moderna COVID-19 vaccine
         </a>
         2023-2024 Formula, Pfizer COVID-19 vaccine 2023-2024 Formula, and
         <a class="drug drug_general" data-topicid="135147" href="/z/d/drug information/135147.html" rel="external">
          Novavax COVID-19 vaccine
         </a>
         2023-2024 Formula), which contain the spike protein from Omicron variant XBB.1.5. (See
         <a class="local">
          'General principles'
         </a>
         above and
         <a class="local">
          'Available vaccines'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for vaccination
         </strong>
         – For all individuals aged six months and older, we suggest a 2023-2024 formula COVID-19 vaccine (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In particular, individuals who are at highest risk of severe outcomes with COVID-19, specifically individuals 65 years or older, immunocompromised individuals, and individuals with multiple medical comorbidities  (
         <a class="graphic graphic_table graphicRef127477" href="/z/d/graphic/127477.html" rel="external">
          table 3
         </a>
         ) are most likely to benefit from vaccination.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Vaccines available in the United States substantially reduce the risk of COVID-19, especially severe/critical disease, and have been associated with substantial reductions in COVID-19-associated hospitalizations and deaths, even in the context of variants that partially evade vaccine-induced immune responses. Although effectiveness wanes, vaccine-induced immunity continues to reduce the risk of severe disease, and repeat vaccination is associated with a relative increase in effectiveness over several months. (See
         <a class="local">
          'Indications and vaccine selection'
         </a>
         above and
         <a class="local">
          'Benefits of vaccination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          How to vaccinate
         </strong>
         – Our approach to COVID-19 vaccination in the United States is in accordance with recommendations from the Centers for Disease Control and Prevention (CDC).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Immunocompetent individuals aged six months to four years
         </strong>
         – Individuals in this age group should receive at least three vaccine doses, at least one of which is a 2023-2024 formula COVID-19 vaccine. The number of doses of the 2023-2024 formula COVID-19 vaccine depends on their vaccination history. (See
         <a class="local">
          'Children aged six months to four years'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Immunocompetent individuals aged five years and older
         </strong>
         – Individuals in this age group should receive one 2023-2024 formula COVID-19 vaccine. This includes individuals who have already received prior vaccine doses. (See
         <a class="local">
          'Children aged 5 to 11 years'
         </a>
         above and
         <a class="local">
          'Adolescents and adults aged 12 years and older'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Individuals aged six months and older with immunocompromising conditions
         </strong>
         – Individuals with immunocompromising conditions  (
         <a class="graphic graphic_table graphicRef132490" href="/z/d/graphic/132490.html" rel="external">
          table 4
         </a>
         ) should receive at least three mRNA vaccine doses or at least two Novavax vaccine doses, at least one of which is a 2023-2024 formula COVID-19 vaccine. The number of doses of the 2023-2024 formula COVID-19 vaccine depends on their vaccination history. (See
         <a class="local">
          'Immunocompromised individuals'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Vaccine doses are presented in the table  (
         <a class="graphic graphic_table graphicRef130711" href="/z/d/graphic/130711.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vaccine safety
         </strong>
         – Severe adverse events with available COVID-19 vaccines are extremely rare and do not outweigh their benefit for recommended indications. The mRNA vaccines and
         <a class="drug drug_general" data-topicid="135147" href="/z/d/drug information/135147.html" rel="external">
          Novavax COVID-19 vaccine
         </a>
         have all been associated with a small excess risk of myocarditis, mainly in male adolescents and young adults. The majority of vaccine-associated myocarditis cases are mild and improve within days. (See
         <a class="local">
          'Myocarditis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Deviations from dosing recommendations
         </strong>
         – If the vaccine is administered in a manner different from the recommended approach, the dose generally does not have to be repeated.
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Fclinical-considerations%2Finterim-considerations-us-appendix.html&amp;token=JEHHJm%2FVE%2Fczu0Kvc1DVQUpygFBTbM3nx%2BQkzEPu166b1PdyYB%2FZy8UUx%2BhLrk1M6M7adxMuNRwuLsclowR%2BInMu5rgfG6pvkqGlpyWY%2BzeDWuJXy7rpwtTo6vB9J89C&amp;TOPIC_ID=129849" target="_blank">
          CDC recommendations on how to manage vaccination errors or deviations
         </a>
         are presented in the table  (
         <a class="graphic graphic_table graphicRef130956" href="/z/d/graphic/130956.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="local">
          'Technique and potential administration errors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Expected side effects
         </strong>
         – Vaccine recipients should be advised that side effects are common and include local and systemic reactions, including pain at the injection site, fever, fatigue, and headache. Analgesics or antipyretics (eg, nonsteroidal anti-inflammatory drugs [NSAIDs] or
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         ) can be taken if these reactions develop, although prophylactic use of these agents before vaccine receipt is generally discouraged because of the uncertain impact on the host immune response to vaccination. (See
         <a class="local">
          'Patient counseling'
         </a>
         above and
         <a class="local">
          'Common adverse effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraindications and precautions
         </strong>
         – The primary contraindications to COVID-19 vaccination are severe or immediate allergic reactions to the vaccine or any of its components. Individuals without a contraindication who have a history of anaphylaxis to other vaccines or injectable therapies, an allergy-related contraindication to a COVID-19 vaccine class other than the one they are receiving, or a nonsevere immediate allergic reaction to a prior COVID-19 vaccine should be monitored for 30 minutes. (See
         <a class="local">
          'Contraindications and precautions (including allergies)'
         </a>
         above and
         <a class="local">
          'Monitoring for immediate reactions to vaccine'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          World Health Organization. Draft landscape of COVID-19 candidate vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (Accessed on October 20, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krammer F. SARS-CoV-2 vaccines in development. Nature 2020; 586:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edwards KM, Dupont WD, Westrich MK, et al. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994; 169:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohmit SE, Victor JC, Rotthoff JR, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006; 355:2513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graepel KW, Kochhar S, Clayton EW, Edwards KE. Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development. J Infect Dis 2020; 222:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graham BS. Rapid COVID-19 vaccine development. Science 2020; 368:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halstead SB, Katzelnick L. COVID-19 Vaccines: Should We Fear ADE? J Infect Dis 2020; 222:1946.
          </a>
         </li>
         <li class="breakAll">
          Brighton Collaboration. Accelerated Assessment of the Risk of Disease Enhancement with COVID-19 Vaccines​, March 2020. https://brightoncollaboration.us/brighton-collaboration-cepi-covid-19-web-conference/ (Accessed on October 20, 2020).
         </li>
         <li class="breakAll">
          SPIKEVAX (COVID-19 Vaccine, mRNA) Suspension for injection, for intramuscular use; 2023-2024 Formula. US Food and Drug Administration (FDA) approved product information. Revised September 11, 2023. https://www.fda.gov/media/155675/download?attachment (Accessed on September 11, 2023).
         </li>
         <li class="breakAll">
          FACT SHEET FOR HEALTHCARE PROVIDERS ADMINISTERING VACCINE:
EMERGENCY USE AUTHORIZATION OF
MODERNA COVID-19 VACCINE (2023-2024 FORMULA),
FOR INDIVIDUALS 6 MONTHS THROUGH 11 YEARS OF AGE https://www.fda.gov/media/167208/download?attachment (Accessed on September 11, 2023).
         </li>
         <li class="breakAll">
          COMIRNATY (COVID-19 Vaccine, mRNA) suspension for injection, for intramuscular use; 2023-2024 Formula. US Food and Drug Administration (FDA) approved product information. Revised September 11, 2023. https://www.fda.gov/media/151707/download?attachment (Accessed on September 11, 2023).
         </li>
         <li class="breakAll">
          FACT SHEET FOR HEALTHCARE PROVIDERS ADMINISTERING VACCINE: EMERGENCY USE
AUTHORIZATION OF PFIZER-BIONTECH COVID-19 VACCINE (2023-2024 FORMULA), FOR
6 MONTHS THROUGH 11 YEARS OF AGE https://www.fda.gov/media/167211/download?attachment (Accessed on September 11, 2023).
         </li>
         <li class="breakAll">
          Recommendation for the 2023-2024 Formula of COVID-19 vaccines in the US. https://www.fda.gov/media/169591/download?attachment (Accessed on September 11, 2023).
         </li>
         <li class="breakAll">
          Emergency Use Authorization (EUA) of the Novavax COVID-19 vaccine, adjuvanted (2023-2024 Formula), for individuals 12 years of age and older https://www.fda.gov/media/159897/download?attachment (Accessed on October 04, 2023).
         </li>
         <li class="breakAll">
          US Food and Drug Administration. Emergency use authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). https://www.fda.gov/media/146304/download (Accessed on March 27, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson MG, Stenehjem E, Grannis S, et al. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. N Engl J Med 2021; 385:1355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 2021; 397:1819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet 2021; 397:1646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med 2021; 384:1412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNamara LA, Wiegand RE, Burke RM, et al. Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data. Lancet 2022; 399:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ioannou GN, Locke ER, O'Hare AM, et al. COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System : A Target Trial Emulation Study. Ann Intern Med 2022; 175:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tenforde MW, Self WH, Gaglani M, et al. Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death - United States, March 2021-January 2022. MMWR Morb Mortal Wkly Rep 2022; 71:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Havers FP, Pham H, Taylor CA, et al. COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022. JAMA Intern Med 2022; 182:1071.
          </a>
         </li>
         <li class="breakAll">
          CDC. COVID-19–Associated Hospitalizations among Infants, Children and Adults — COVID-NET, January– August 2023. Presented September 12, 2023. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-09-12/03-COVID-Havers-508.pdf (Accessed on September 12, 2023).
         </li>
         <li class="breakAll">
          Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html (Accessed on April 26, 2023).
         </li>
         <li class="breakAll">
          Oliver S. Updates to COVID-19 vaccine policy: Considerations for future planning. Presented at the ACIP meeting on April 19, 2023. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-04-19/06-COVID-Oliver-508.pdf (Accessed on April 20, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones JM, Manrique IM, Stone MS, et al. Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections Among Blood Donors, by COVID-19 Vaccination Status - United States, April 2021-September 2022. MMWR Morb Mortal Wkly Rep 2023; 72:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klaassen F, Chitwood MH, Cohen T, et al. Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022. Clin Infect Dis 2023; 77:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor CA, Patel K, Patton ME, et al. COVID-19-Associated Hospitalizations Among U.S. Adults Aged ≥65 Years - COVID-NET, 13 States, January-August 2023. MMWR Morb Mortal Wkly Rep 2023; 72:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atmar RL, Lyke KE, Deming ME, et al. Homologous and Heterologous Covid-19 Booster Vaccinations. N Engl J Med 2022; 386:1046.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sablerolles RSG, Rietdijk WJR, Goorhuis A, et al. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming. N Engl J Med 2022; 386:951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munro APS, Feng S, Janani L, et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infect Dis 2022; 22:1131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayr FB, Talisa VB, Shaikh O, et al. Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans. N Engl J Med 2022; 386:1375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Natarajan K, Prasad N, Dascomb K, et al. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson &amp; Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022. MMWR Morb Mortal Wkly Rep 2022; 71:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Accorsi EK, Britton A, Shang N, et al. Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron. N Engl J Med 2022; 386:2433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazarus R, Baos S, Cappel-Porter H, et al. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet 2021; 398:2277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elias MD, Truong DT, Oster ME, et al. Examination of Adverse Reactions After COVID-19 Vaccination Among Patients With a History of Multisystem Inflammatory Syndrome in Children. JAMA Netw Open 2023; 6:e2248987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhong D, Xiao S, Debes AK, et al. Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection. JAMA 2021; 326:2524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reynolds CJ, Pade C, Gibbons JM, et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science 2021; 372:1418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stamatatos L, Czartoski J, Wan YH, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science 2021; 372:1413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chin ET, Leidner D, Zhang Y, et al. Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a Prison. N Engl J Med 2021; 385:2300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hammerman A, Sergienko R, Friger M, et al. Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19. N Engl J Med 2022; 386:1221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gazit S, Shlezinger R, Perez G, et al. The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine : A Retrospective Cohort Study. Ann Intern Med 2022; 175:674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. N Engl J Med 2022; 386:1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cerqueira-Silva T, Andrews JR, Boaventura VS, et al. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. Lancet Infect Dis 2022; 22:791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nordström P, Ballin M, Nordström A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Lancet Infect Dis 2022; 22:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carazo S, Skowronski DM, Brisson M, et al. Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada. JAMA Netw Open 2022; 5:e2236670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chin ET, Leidner D, Lamson L, et al. Protection against Omicron from Vaccination and Previous Infection in a Prison System. N Engl J Med 2022; 387:1770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. JAMA 2021; 326:1930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldberg Y, Mandel M, Bar-On YM, et al. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. N Engl J Med 2022; 386:2201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bozio CH, Grannis SJ, Naleway AL, et al. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           León TM, Dorabawila V, Nelson L, et al. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021. MMWR Morb Mortal Wkly Rep 2022; 71:125.
          </a>
         </li>
         <li class="breakAll">
          UK Health Security Agency. The effectiveness of vaccination against long COVID: A rapid evidence briefing. https://ukhsa.koha-ptfs.co.uk/cgi-bin/koha/opac-retrieve-file.pl?id=fe4f10cd3cd509fe045ad4f72ae0dfff (Accessed on February 24, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krammer F, Srivastava K, Alshammary H, et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med 2021; 384:1372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis 2021; 21:939.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Updated healthcare infection prevention and control recommendations in response to COVID-19 vaccination. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-after-vaccination.html (Accessed on May 05, 2021).
         </li>
         <li class="breakAll">
          General Principles of COVID-19 Vaccines for Immunocompromised Patients https://www.hematology.org/covid-19/ash-astct-covid-19-and-vaccines (Accessed on February 21, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chodick G, Tene L, Rotem RS, et al. The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data. Clin Infect Dis 2022; 74:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tenforde MW, Patel MM, Ginde AA, et al. Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States. Clin Infect Dis 2022; 74:1515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clin Microbiol Infect 2021; 27:1652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Embi PJ, Levy ME, Naleway AL, et al. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aslam S, Adler E, Mekeel K, Little SJ. Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients. Transpl Infect Dis 2021; 23:e13705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun J, Zheng Q, Madhira V, et al. Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US. JAMA Intern Med 2022; 182:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee ARYB, Wong SY, Chai LYA, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ 2022; 376:e068632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Risk M, Hayek SS, Schiopu E, et al. COVID-19 vaccine effectiveness against omicron (B.1.1.529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective cohort study. Lancet Rheumatol 2022; 4:e775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA 2021; 325:2204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marion O, Del Bello A, Abravanel F, et al. Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants. Ann Intern Med 2021; 174:1336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Redjoul R, Le Bouter A, Beckerich F, et al. Antibody response after second BNT162b2 dose in allogeneic HSCT recipients. Lancet 2021; 398:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazzola A, Todesco E, Drouin S, et al. Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients. Clin Infect Dis 2022; 74:1093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moor MB, Suter-Riniker F, Horn MP, et al. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatol 2021; 3:e789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bitoun S, Henry J, Desjardins D, et al. Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases. Arthritis Rheumatol 2022; 74:927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tenforde MW, Patel MM, Gaglani M, et al. Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021. MMWR Morb Mortal Wkly Rep 2022; 71:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Britton A, Embi PJ, Levy ME, et al. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022. MMWR Morb Mortal Wkly Rep 2022; 71:1335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamar N, Abravanel F, Marion O, et al. Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. N Engl J Med 2021; 385:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Werbel WA, Boyarsky BJ, Ou MT, et al. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Ann Intern Med 2021; 174:1330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Longlune N, Nogier MB, Miedougé M, et al. High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients. Nephrol Dial Transplant 2021; 36:1704.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benotmane I, Gautier G, Perrin P, et al. Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses. JAMA 2021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hall VG, Ferreira VH, Ku T, et al. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. N Engl J Med 2021; 385:1244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caillard S, Thaunat O, Benotmane I, et al. Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series. Ann Intern Med 2022; 175:455.
          </a>
         </li>
         <li class="breakAll">
          American College of Rheumatology. COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases. Available at: https://www.rheumatology.org/Portals/0/Files/COVID-19-Vaccine-Clinical-Guidance-Rheumatic-Diseases-Summary.pdf (Accessed on March 04, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barnes E, Goodyear CS, Willicombe M, et al. SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nat Med 2023; 29:1760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frenck RW Jr, Klein NP, Kitchin N, et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med 2021; 385:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muñoz FM, Sher LD, Sabharwal C, et al. Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age. N Engl J Med 2023; 388:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ali K, Berman G, Zhou H, et al. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. N Engl J Med 2021; 385:2241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Creech CB, Anderson E, Berthaud V, et al. Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age. N Engl J Med 2022; 386:2011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson EJ, Creech CB, Berthaud V, et al. Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age. N Engl J Med 2022; 387:1673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. N Engl J Med 2022; 386:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleming-Dutra KE, Britton A, Shang N, et al. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance. JAMA 2022; 327:2210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowlkes AL, Yoon SK, Lutrick K, et al. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022. MMWR Morb Mortal Wkly Rep 2022; 71:422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Price AM, Olson SM, Newhams MM, et al. BNT162b2 Protection against the Omicron Variant in Children and Adolescents. N Engl J Med 2022; 386:1899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shi DS, Whitaker M, Marks KJ, et al. Hospitalizations of Children Aged 5-11 Years with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 2020-February 2022. MMWR Morb Mortal Wkly Rep 2022; 71:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dorabawila V, Hoefer D, Bauer UE, et al. Risk of Infection and Hospitalization Among Vaccinated and Unvaccinated Children and Adolescents in New York After the Emergence of the Omicron Variant. JAMA 2022; 327:2242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen-Stavi CJ, Magen O, Barda N, et al. BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age. N Engl J Med 2022; 387:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sacco C, Del Manso M, Mateo-Urdiales A, et al. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022. Lancet 2022; 400:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan SHX, Cook AR, Heng D, et al. Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age. N Engl J Med 2022; 387:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin DY, Gu Y, Xu Y, et al. Effects of Vaccination and Previous Infection on Omicron Infections in Children. N Engl J Med 2022; 387:1141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chemaitelly H, AlMukdad S, Ayoub HH, et al. Covid-19 Vaccine Protection among Children and Adolescents in Qatar. N Engl J Med 2022; 387:1865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jang EJ, Choe YJ, Kim RK, Park YJ. BNT162b2 Vaccine Effectiveness Against the SARS-CoV-2 Omicron Variant in Children Aged 5 to 11 Years. JAMA Pediatr 2023; 177:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watanabe A, Kani R, Iwagami M, et al. Assessment of Efficacy and Safety of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years: A Systematic Review and Meta-analysis. JAMA Pediatr 2023; 177:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piechotta V, Siemens W, Thielemann I, et al. Safety and effectiveness of vaccines against COVID-19 in children aged 5-11 years: a systematic review and meta-analysis. Lancet Child Adolesc Health 2023; 7:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin DY, Xu Y, Gu Y, et al. Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study. Lancet Infect Dis 2023; 23:1257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tartof SY, Frankland TB, Slezak JM, et al. Receipt of BNT162b2 Vaccine and COVID-19 Ambulatory Visits in US Children Younger Than 5 Years. JAMA 2023; 330:1282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson EJ, Campbell JD, Creech CB, et al. Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral? Clin Infect Dis 2021; 73:336.
          </a>
         </li>
         <li class="breakAll">
          Wallace M. Evidence to Recommendations Framework: 2023 – 2024 (Monovalent, XBB Containing) COVID-19 Vaccine
. Presented at ACIP meeting September 12, 2023. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-09-12/11-COVID-Wallace-508.pdf (Accessed on September 12, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nygaard U, Holm M, Dungu KHS, et al. Risk of Myopericarditis After COVID-19 Vaccination in Danish Children Aged 5 to 11 Years. Pediatrics 2022; 150.
          </a>
         </li>
         <li class="breakAll">
          Vaccines and Related Biological Products Advisory Committee Meeting.  FDA Briefing Document: EUA amendment request for use of the Moderna COVID-19 Vaccine in children 6 months through 17 years of age. June 14-15, 2022 https://www.fda.gov/media/159189/download (Accessed on June 16, 2022).
         </li>
         <li class="breakAll">
          Vaccines and Related Biological Products Advisory Committee Meeting. FDA Briefing Document: EUA amendment request for Pfizer-BioNTech COVID-19 Vaccine for use in children 6 months through 4 years of age, June 15, 2022. https://www.fda.gov/media/159195/download (Accessed on June 17, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hause AM, Baggs J, Marquez P, et al. COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1755.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. COVID-19 vaccine safety update: Primary series in young children and booster doses in older children and adults. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-09-01/05-COVID-Shimabukuro-508.pdf (Accessed on September 05, 2022).
         </li>
         <li class="breakAll">
          Olivier S. Evidence to Recommendations (EtR) Framework: Pfizer-BioNTech COVID-19 vaccine in children aged 5–11 years. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-11-2-3/08-COVID-Oliver-508.pdf (Accessed on November 03, 2021).
         </li>
         <li class="breakAll">
          Yang H. Benefits-Risks of Pfizer-BioNTech COVID-19 Vaccine for Ages 5 to 11 Years. https://www.fda.gov/media/153507/download (Accessed on November 02, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salzman MB, Huang CW, O'Brien CM, Castillo RD. Multisystem Inflammatory Syndrome after SARS-CoV-2 Infection and COVID-19 Vaccination. Emerg Infect Dis 2021; 27:1944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yousaf AR, Cortese MM, Taylor AW, et al. Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation. Lancet Child Adolesc Health 2022; 6:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortese MM, Taylor AW, Akinbami LJ, et al. Surveillance for Multisystem Inflammatory Syndrome in US Children Aged 5-11 Years Who Received Pfizer-BioNTech COVID-19 Vaccine, November 2021 through March 2022. J Infect Dis 2023; 228:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy M, Recher M, Hubert H, et al. Multisystem Inflammatory Syndrome in Children by COVID-19 Vaccination Status of Adolescents in France. JAMA 2022; 327:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zambrano LD, Newhams MM, Olson SM, et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021. MMWR Morb Mortal Wkly Rep 2022; 71:52.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Vaccines for Children Program (VFC). https://www.cdc.gov/vaccines/programs/vfc/ (Accessed on November 05, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitney CG, Zhou F, Singleton J, et al. Benefits from immunization during the vaccines for children program era - United States, 1994-2013. MMWR Morb Mortal Wkly Rep 2014; 63:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hermann EA, Lee B, Balte PP, et al. Association of Symptoms After COVID-19 Vaccination With Anti-SARS-CoV-2 Antibody Response in the Framingham Heart Study. JAMA Netw Open 2022; 5:e2237908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Debes AK, Xiao S, Colantuoni E, et al. Association of Vaccine Type and Prior SARS-CoV-2 Infection With Symptoms and Antibody Measurements Following Vaccination Among Health Care Workers. JAMA Intern Med 2021; 181:1660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapin-Bardales J, Gee J, Myers T. Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines. JAMA 2021; 325:2201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet 2009; 374:1339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doedée AM, Boland GJ, Pennings JL, et al. Effects of prophylactic and therapeutic paracetamol treatment during vaccination on hepatitis B antibody levels in adults: two open-label, randomized controlled trials. PLoS One 2014; 9:e98175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Syncope after vaccination--United States, January 2005-July 2007. MMWR Morb Mortal Wkly Rep 2008; 57:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maayan H, Kirgner I, Gutwein O, et al. Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine. J Thromb Haemost 2021; 19:2314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matheny M, Maleque N, Channell N, et al. Severe Exacerbations of Systemic Capillary Leak Syndrome After COVID-19 Vaccination: A Case Series. Ann Intern Med 2021; 174:1476.
          </a>
         </li>
         <li class="breakAll">
          American Society of Hematology. Thrombosis with Thrombocytopenia Syndrome (also termed Vaccine-induced Thrombotic Thrombocytopenia). https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia (Accessed on April 24, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blumenthal KG, Freeman EE, Saff RR, et al. Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2. N Engl J Med 2021; 384:1273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blumenthal KG, Saff RR, Freeman EE. Delayed Large Local Reactions to mRNA Vaccines. Reply. N Engl J Med 2021; 384:e98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casajuana J, Iglesias B, Fàbregas M, et al. Safety of intramuscular influenza vaccine in patients receiving oral anticoagulation therapy: a single blinded multi-centre randomized controlled clinical trial. BMC Blood Disord 2008; 8:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bohnert AS, Kumbier K, Rowneki M, et al. Adverse outcomes of SARS-CoV-2 infection with delta and omicron variants in vaccinated versus unvaccinated US veterans: retrospective cohort study. BMJ 2023; 381:e074521.
          </a>
         </li>
         <li class="breakAll">
          Link-Gelles R. Updates on COVID-19 Vaccine Effectiveness during Omicron. ACIP meeting, September 1, 2022. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-09-01/04-COVID-Link-Gelles-508.pdf (Accessed on September 02, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu S, Huang R, Sy LS, et al. COVID-19 Vaccination and Non-COVID-19 Mortality Risk - Seven Integrated Health Care Organizations, United States, December 14, 2020-July 31, 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas SJ, Moreira ED Jr, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med 2021; 385:1761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med 2021; 385:1774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. N Engl J Med 2022; 386:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson AG, Linde L, Payne AB, et al. Notes from the Field: Comparison of COVID-19 Mortality Rates Among Adults Aged ≥65 Years Who Were Unvaccinated and Those Who Received a Bivalent Booster Dose Within the Preceding 6 Months - 20 U.S. Jurisdictions, September 18, 2022-April 1, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin DY, Gu Y, Xu Y, et al. Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes. JAMA 2022; 328:1415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CDC COVID-19 Vaccine Breakthrough Case Investigations Team. COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021. MMWR Morb Mortal Wkly Rep 2021; 70:792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. N Engl J Med 2021; 385:1474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tenforde MW, Self WH, Adams K, et al. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA 2021; 326:2043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim YE, Huh K, Park YJ, et al. Association Between Vaccination and Acute Myocardial Infarction and Ischemic Stroke After COVID-19 Infection. JAMA 2022; 328:887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yek C, Warner S, Wiltz JL, et al. Risk Factors for Severe COVID-19 Outcomes Among Persons Aged ≥18 Years Who Completed a Primary COVID-19 Vaccination Series - 465 Health Care Facilities, United States, December 2020-October 2021. MMWR Morb Mortal Wkly Rep 2022; 71:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiang J, Chan L, Kauffman J, et al. Impact of Vaccination on Major Adverse Cardiovascular Events in Patients With COVID-19 Infection. J Am Coll Cardiol 2023; 81:928.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grange Z, Buelo A, Sullivan C, et al. Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland. Lancet 2021; 398:1799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tenforde MW, Self WH, Naioti EA, et al. Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldberg Y, Mandel M, Bar-On YM, et al. Waning Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med 2021; 385:e85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrews N, Tessier E, Stowe J, et al. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. N Engl J Med 2022; 386:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep 2022; 71:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferdinands JM, Rao S, Dixon BE, et al. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. BMJ 2022; 379:e072141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeCuir J, Surie D, Zhu Y, et al. Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period - IVY Network, 19 U.S. States, February 1, 2022-January 31, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirsebom FCM, Andrews N, Stowe J, et al. Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study. Lancet Infect Dis 2023; 23:1235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Surie D, DeCuir J, Zhu Y, et al. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years - IVY Network, 18 States, September 8-November 30, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:1625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tenforde MW, Weber ZA, Natarajan K, et al. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. MMWR Morb Mortal Wkly Rep 2022; 71:1616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin DY, Xu Y, Gu Y, et al. Effectiveness of Bivalent Boosters against Severe Omicron Infection. N Engl J Med 2023; 388:764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson AG, Linde L, Ali AR, et al. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination - 24 U.S. Jurisdictions, October 3, 2021-December 24, 2022. MMWR Morb Mortal Wkly Rep 2023; 72:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arbel R, Peretz A, Sergienko R, et al. Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study. Lancet Infect Dis 2023; 23:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bar-On YM, Goldberg Y, Mandel M, et al. Protection against Covid-19 by BNT162b2 Booster across Age Groups. N Engl J Med 2021; 385:2421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet 2021; 398:2093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arbel R, Hammerman A, Sergienko R, et al. BNT162b2 Vaccine Booster and Mortality Due to Covid-19. N Engl J Med 2021; 385:2413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ioannou GN, Bohnert ASB, O'Hare AM, et al. Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era. Ann Intern Med 2022; 175:1693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lai FTT, Yan VKC, Ye X, et al. Booster vaccination with inactivated whole-virus or mRNA vaccines and COVID-19-related deaths among people with multimorbidity: a cohort study. CMAJ 2023; 195:E143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bar-On YM, Goldberg Y, Mandel M, et al. Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. N Engl J Med 2022; 386:1712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arbel R, Sergienko R, Friger M, et al. Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years. Nat Med 2022; 28:1486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magen O, Waxman JG, Makov-Assif M, et al. Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med 2022; 386:1603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wee LE, Pang D, Chiew C, et al. Long-term Real-world Protection Afforded by Third mRNA Doses Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections, Coronavirus Disease 19-related Emergency Attendances and Hospitalizations Amongst Older Singaporeans During an Omicron XBB Wave. Clin Infect Dis 2023; 77:1111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA 2022; 327:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep 2022; 71:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med 2022; 28:1063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ 2022; 376:e069761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. N Engl J Med 2022; 386:1804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med 2022; 386:1532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. N Engl J Med 2022; 387:21.
          </a>
         </li>
         <li class="breakAll">
          Discovery Health, South Africa’s largest private health insurance administrator, releases at-scale, real-world analysis of Omicron outbreak based on 211,000 COVID-19 test results in South Africa, including collaboration with South
Africa. https://www.discovery.co.za/corporate/health-insights-omicron-outbreak-analysis (Accessed on December 17, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collie S, Champion J, Moultrie H, et al. Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. N Engl J Med 2022; 386:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Surie D, Bonnell L, Adams K, et al. Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:1327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu N, Joyal-Desmarais K, Ribeiro PAB, et al. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. Lancet Respir Med 2023; 11:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Link-Gelles R, Weber ZA, Reese SE, et al. Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023. MMWR Morb Mortal Wkly Rep 2023; 72:579.
          </a>
         </li>
         <li class="breakAll">
          FDA Briefing Document. Pfizer-BioNTech COVID-19 Vaccine. Vaccines and Related Biological Products Advisory Committee Meeting. December 10, 2020 https://www.fda.gov/media/144245/download (Accessed on December 09, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020; 383:2603.
          </a>
         </li>
         <li class="breakAll">
          US FDA. Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) for 5 through 11 years of age. https://www.fda.gov/media/153714/download (Accessed on November 02, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021; 384:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heath PT, Galiza EP, Baxter DN, et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N Engl J Med 2021; 385:1172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Áñez G, Dunkle LM, Gay CL, et al. Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial. JAMA Netw Open 2023; 6:e239135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Britton A, Fleming-Dutra KE, Shang N, et al. Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance. JAMA 2022; 327:1032.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenberg ES, Holtgrave DR, Dorabawila V, et al. New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status - New York, May 3-July 25, 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nanduri S, Pilishvili T, Derado G, et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med 2021; 385:e83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet 2021; 398:1407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baden LR, El Sahly HM, Essink B, et al. Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge. N Engl J Med 2021; 385:2485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohn BA, Cirillo PM, Murphy CC, et al. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. Science 2022; 375:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Israel A, Merzon E, Schäffer AA, et al. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study. BMJ 2021; 375:e067873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abu-Raddad LJ, Chemaitelly H, Bertollini R, National Study Group for COVID-19 Vaccination. Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar. N Engl J Med 2022; 386:1091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nordström P, Ballin M, Nordström A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet 2022; 399:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 2022; 399:924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menegale F, Manica M, Zardini A, et al. Evaluation of Waning of SARS-CoV-2 Vaccine-Induced Immunity: A Systematic Review and Meta-analysis. JAMA Netw Open 2023; 6:e2310650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mateo-Urdiales A, Sacco C, Petrone D, et al. Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373 Against COVID-19. JAMA Netw Open 2023; 6:e2336854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Link-Gelles R, Ciesla AA, Fleming-Dutra KE, et al. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022. MMWR Morb Mortal Wkly Rep 2022; 71:1526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin DY, Xu Y, Gu Y, et al. Durability of Bivalent Boosters against Omicron Subvariants. N Engl J Med 2023; 388:1818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreira ED Jr, Kitchin N, Xu X, et al. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. N Engl J Med 2022; 386:1910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spitzer A, Angel Y, Marudi O, et al. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel. JAMA 2022; 327:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tai CG, Maragakis LL, Connolly S, et al. Association Between COVID-19 Booster Vaccination and Omicron Infection in a Highly Vaccinated Cohort of Players and Staff in the National Basketball Association. JAMA 2022; 328:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amir O, Goldberg Y, Mandel M, et al. Initial protection against SARS-CoV-2 omicron lineage infection in children and adolescents by BNT162b2 in Israel: an observational study. Lancet Infect Dis 2023; 23:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arashiro T, Arima Y, Kuramochi J, et al. Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan. Open Forum Infect Dis 2023; 10:ofad240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis 2022; 22:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med 2022; 28:1461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azzolini E, Levi R, Sarti R, et al. Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers. JAMA 2022; 328:676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Byambasuren O, Stehlik P, Clark J, et al. Effect of covid-19 vaccination on long covid: systematic review. BMJ Med 2023; 2:e000385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eyre DW, Taylor D, Purver M, et al. Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants. N Engl J Med 2022; 386:744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singanayagam A, Hakki S, Dunning J, et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis 2022; 22:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kissler SM, Fauver JR, Mack C, et al. Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons. N Engl J Med 2021; 385:2489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puhach O, Adea K, Hulo N, et al. Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2. Nat Med 2022; 28:1491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jung J, Kim JY, Park H, et al. Transmission and Infectious SARS-CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated Individuals. JAMA Netw Open 2022; 5:e2213606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chia PY, Ong SWX, Chiew CJ, et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. Clin Microbiol Infect 2022; 28:612.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan ST, Kwan AT, Rodríguez-Barraquer I, et al. Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. Nat Med 2023; 29:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoeve CE, de Gier B, Huiberts AJ, et al. Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Delta and Omicron Infection and Infectiousness Within Households in the Netherlands Between July 2021 and August 2022. J Infect Dis 2023; 228:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mongin D, Bürgisser N, Laurie G, et al. Effect of SARS-CoV-2 prior infection and mRNA vaccination on contagiousness and susceptibility to infection. Nat Commun 2023; 14:5452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grannis SJ, Rowley EA, Ong TC, et al. Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19-Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance - Nine States, June-August 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pilishvili T, Gierke R, Fleming-Dutra KE, et al. Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel. N Engl J Med 2021; 385:e90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickerman BA, Gerlovin H, Madenci AL, et al. Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans. N Engl J Med 2022; 386:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bajema KL, Dahl RM, Evener SL, et al. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abu-Raddad LJ, Chemaitelly H, Bertollini R, National Study Group for COVID-19 Vaccination. Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar. N Engl J Med 2022; 386:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang L, Davis PB, Kaelber DC, et al. Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period. JAMA 2022; 327:678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Islam N, Sheils NE, Jarvis MS, Cohen K. Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine. Nat Commun 2022; 13:2377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hulme WJ, Horne EMF, Parker EPK, et al. Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP. BMJ 2023; 380:e072808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickerman BA, Madenci AL, Gerlovin H, et al. Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans. JAMA Intern Med 2022; 182:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med 2021; 27:2032.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 2022; 375:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goel RR, Painter MM, Apostolidis SA, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 2021; 374:abm0829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu J, Chandrashekar A, Sellers D, et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature 2022; 603:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keeton R, Tincho MB, Ngomti A, et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature 2022; 603:488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarke A, Coelho CH, Zhang Z, et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell 2022; 185:847.
          </a>
         </li>
         <li class="breakAll">
          Safety and Immunogenicity of Moderna COVID-19 Vaccine (2023-2024 Formula)
Monovalent XBB.1.5 Variant Vaccine. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-09-12/08-COVID-Priddy-508.pdf (Accessed on September 12, 2023).
         </li>
         <li class="breakAll">
          Monovalent XBB.1.5 BNT162b2 COVID-19 Vaccine. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-09-12/10-COVID-Modjarrad-508.pdf (Accessed on September 12, 2023).
         </li>
         <li class="breakAll">
          Data in Support of Novavax XBB.1.5 Vaccine https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-09-12/09-COVID-Dubovsky-508.pdf (Accessed on September 12, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gee J, Marquez P, Su J, et al. First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021. MMWR Morb Mortal Wkly Rep 2021; 70:283.
          </a>
         </li>
         <li class="breakAll">
          FDA Briefing Document. Moderna COVID-19 Vaccine. https://www.fda.gov/media/144434/download (Accessed on December 16, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hause AM, Marquez P, Zhang B, et al. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hause AM, Marquez P, Zhang B, et al. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:1401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goddard K, Donahue JG, Lewis N, et al. Safety of COVID-19 mRNA Vaccination Among Young Children in the Vaccine Safety Datalink. Pediatrics 2023; 152.
          </a>
         </li>
         <li class="breakAll">
          Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 3-6 May 2021 https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-3-6-may-2021 (Accessed on May 26, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021. MMWR Morb Mortal Wkly Rep 2021; 70:977.
          </a>
         </li>
         <li class="breakAll">
          Vaccines and Related Biological Products Advisory Committee Meeting. FDA Briefing Document: Novavax COVID-19 Vaccine. June 7, 2022 https://www.fda.gov/media/158912/download (Accessed on June 16, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oster ME, Shay DK, Su JR, et al. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. JAMA 2022; 327:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goddard K, Hanson KE, Lewis N, et al. Incidence of Myocarditis/Pericarditis Following mRNA COVID-19 Vaccination Among Children and Younger Adults in the United States. Ann Intern Med 2022; 175:1169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med 2021; 385:2140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med 2021; 385:2132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lai FTT, Li X, Peng K, et al. Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine : A Case-Control Study. Ann Intern Med 2022; 175:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 Vaccination in Israeli Adolescents. N Engl J Med 2022; 386:998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buchan SA, Alley S, Seo CY, et al. Myocarditis or Pericarditis Events After BNT162b2 Vaccination in Individuals Aged 12 to 17 Years in Ontario, Canada. JAMA Pediatr 2023; 177:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Husby A, Hansen JV, Fosbøl E, et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ 2021; 375:e068665.
          </a>
         </li>
         <li class="breakAll">
          Myocarditis and Pericarditis after COVID-19 mRNA Vaccines https://www.publichealthontario.ca/-/media/documents/ncov/vaccines/2021/11/myocarditis-pericarditis-mrna-vaccines.pdf?sc_lang=en (Accessed on January 28, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karlstad Ø, Hovi P, Husby A, et al. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. JAMA Cardiol 2022; 7:600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Vu S, Bertrand M, Jabagi MJ, et al. Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines. Nat Commun 2022; 13:3633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buchan SA, Seo CY, Johnson C, et al. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada. JAMA Netw Open 2022; 5:e2218505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Block JP, Boehmer TK, Forrest CB, et al. Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination - PCORnet, United States, January 2021-January 2022. MMWR Morb Mortal Wkly Rep 2022; 71:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Witberg G, Magen O, Hoss S, et al. Myocarditis after BNT162b2 Vaccination in Israeli Adolescents. N Engl J Med 2022; 387:1816.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Husby A, Gulseth HL, Hovi P, et al. Clinical outcomes of myocarditis after SARS-CoV-2 mRNA vaccination in four Nordic countries: population based cohort study. BMJ Med 2023; 2:e000373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verma AK, Lavine KJ, Lin CY. Myocarditis after Covid-19 mRNA Vaccination. N Engl J Med 2021; 385:1332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu KY, Butler CR, Koshman S, et al. Persistent myopericarditis after heterologous SARS-CoV-2 mRNA vaccination. CMAJ 2023; 195:E584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cho JY, Kim KH, Lee N, et al. COVID-19 vaccination-related myocarditis: a Korean nationwide study. Eur Heart J 2023; 44:2234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Truong DT, Dionne A, Muniz JC, et al. Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults: Suspected Myocarditis After COVID-19 Vaccination. Circulation 2022; 145:345.
          </a>
         </li>
         <li class="breakAll">
          Updated GTH statement on vaccination with the AstraZeneca COVID-19 vaccine, as of March 22, 2021. https://gth-online.org/wp-content/uploads/2021/03/GTH_Stellungnahme_AstraZeneca_engl._3_22_2021.pdf (Accessed on March 28, 2021).
         </li>
         <li class="breakAll">
          Pai M, Grill A, Ivers A, et al. Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) Following AstraZeneca COVID-19 Vaccination. https://covid19-sciencetable.ca/sciencebrief/vaccine-induced-prothrombotic-immune-thrombocytopenia-vipit-following-astrazeneca-covid-19-vaccination/ (Accessed on March 31, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med 2021; 384:2124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med 2021; 384:2092.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muir KL, Kallam A, Koepsell SA, Gundabolu K. Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination. N Engl J Med 2021; 384:1964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           See I, Su JR, Lale A, et al. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. JAMA 2021; 325:2448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pavord S, Scully M, Hunt BJ, et al. Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis. N Engl J Med 2021; 385:1680.
          </a>
         </li>
         <li class="breakAll">
          Updates on Thrombosis with Thrombocytopenia Syndrome (TTS). ACIP Meeting December 16, 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-12-16/02-COVID-See-508.pdf (Accessed on December 17, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacNeil JR, Su JR, Broder KR, et al. Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson &amp; Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021. MMWR Morb Mortal Wkly Rep 2021; 70:651.
          </a>
         </li>
         <li class="breakAll">
          European Medicines Agency. COVID-19 Vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. https://www.ema.europa.eu/en/news/covid-19-vaccine-janssen-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood (Accessed on May 10, 2021).
         </li>
         <li class="breakAll">
          European Medicines Agency. AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood (Accessed on April 07, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hippisley-Cox J, Patone M, Mei XW, et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ 2021; 374:n1931.
          </a>
         </li>
         <li class="breakAll">
          European Medicines Agency. https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots (Accessed on March 18, 2021).
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Thrombosis with thrombocytopenia syndrome (TTS) following Janssen COVID-19 vaccine. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-04-23/03-COVID-Shimabukuro-508.pdf (Accessed on April 23, 2021).
         </li>
         <li class="breakAll">
          FDA NEWS RELEASE. Coronavirus (COVID-19) Update: July 13, 2021 fda.gov/news-events/press-announcements/coronavirus-covid-19-update-july-13-2021 (Accessed on July 15, 2021).
         </li>
         <li class="breakAll">
          COVID-19 vaccine safety update. COVID-19 VACCINE JANSSEN ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-14-july-2021_en.pdf (Accessed on July 15, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abu-Rumeileh S, Abdelhak A, Foschi M, et al. Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol 2021; 268:1133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonnell EP, Altomare NJ, Parekh YH, et al. COVID-19 as a Trigger of Recurrent Guillain-Barré Syndrome. Pathogens 2020; 9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patone M, Handunnetthi L, Saatci D, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med 2021; 27:2144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woo EJ, Mba-Jonas A, Dimova RB, et al. Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021. JAMA 2021; 326:1606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanson KE, Goddard K, Lewis N, et al. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink. JAMA Netw Open 2022; 5:e228879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abara WE, Gee J, Marquez P, et al. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States. JAMA Netw Open 2023; 6:e2253845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenblum HG, Hadler SC, Moulia D, et al. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson &amp; Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1094.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keh RYS, Scanlon S, Datta-Nemdharry P, et al. COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database. Brain 2023; 146:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen CM, Ramsamy S, Tarr AW, et al. Guillain-Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination. Ann Neurol 2021; 90:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maramattom BV, Krishnan P, Paul R, et al. Guillain-Barré Syndrome following ChAdOx1-S/nCoV-19 Vaccine. Ann Neurol 2021; 90:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li X, Raventós B, Roel E, et al. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis. BMJ 2022; 376:e068373.
          </a>
         </li>
         <li class="breakAll">
          CDC and FDA identify preliminary COVID-19 vaccine safety signal for persons aged 65 years and older. US Food and Drug Administration. Available at: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/cdc-and-fda-identify-preliminary-covid-19-vaccine-safety-signal-persons-aged-65-years-and-older (Accessed on February 02, 2023).
         </li>
         <li class="breakAll">
          COVID-19 mRNA bivalent booster vaccine safety: Vaccines and Related Biological Products Advisory Committee meeting. US Food and Drug Administration. Available at: https://www.fda.gov/media/164811/download (Accessed on February 02, 2023).
         </li>
         <li class="breakAll">
          Yamin D, Yechezkel M, Arbel R, et al. Safety of COVID-19 Monovalent and Bivalent BNT162b2 mRNA Vaccine Boosters for Adults 60 Years and Above: A Large-Scale Retrospective Study. UNPUBLISHED. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4336133 (Accessed on February 02, 2023).
         </li>
         <li class="breakAll">
          Forshee, R. Update on original COVID-19 vaccine and COVID-19 vaccine, bivalent effectiveness and safety. US Food and Drug Administration. https://www.fda.gov/media/164815/download (Accessed on February 02, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jabagi MJ, Bertrand M, Botton J, et al. Stroke, Myocardial Infarction, and Pulmonary Embolism after Bivalent Booster. N Engl J Med 2023; 388:1431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrews N, Stowe J, Miller E, Ramsay M. BA.1 Bivalent COVID-19 Vaccine Use and Stroke in England. JAMA 2023; 330:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banerji A, Wickner PG, Saff R, et al. mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach. J Allergy Clin Immunol Pract 2021; 9:1423.
          </a>
         </li>
         <li class="breakAll">
          Shimabukuro T. COVID-19 vaccine safety update, Advisory Committee on Immunization Practices (ACIP) meeting, January 27, 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-01/06-COVID-Shimabukuro.pdf (Accessed on January 28, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shimabukuro T. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021. Am J Transplant 2021; 21:1326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein NP, Lewis N, Goddard K, et al. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA 2021; 326:1390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shimabukuro TT, Cole M, Su JR. Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021. JAMA 2021; 325:1101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenhawt M, Abrams EM, Shaker M, et al. The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. J Allergy Clin Immunol Pract 2021; 9:3546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warren CM, Snow TT, Lee AS, et al. Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System. JAMA Netw Open 2021; 4:e2125524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khalid MB, Frischmeyer-Guerrerio PA. The conundrum of COVID-19 mRNA vaccine-induced anaphylaxis. J Allergy Clin Immunol Glob 2023; 2:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takano T, Hirose M, Yamasaki Y, et al. Investigation of the incidence of immunisation stress-related response following COVID-19 vaccination in healthcare workers. J Infect Chemother 2022; 28:735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CDC COVID-19 Response Team, Food and Drug Administration. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep 2021; 70:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wesselink AK, Hatch EE, Rothman KJ, et al. A Prospective Cohort Study of COVID-19 Vaccination, SARS-CoV-2 Infection, and Fertility. Am J Epidemiol 2022; 191:1383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen F, Zhu S, Dai Z, et al. Effects of COVID-19 and mRNA vaccines on human fertility. Hum Reprod 2021; 37:5.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Vaccine Safety Datalink (VSD). https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/index.html (Accessed on November 05, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCarthy NL, Gee J, Weintraub E, et al. Monitoring vaccine safety using the Vaccine Safety Datalink: utilizing immunization registries for pandemic influenza. Vaccine 2011; 29:4891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yih WK, Lee GM, Lieu TA, et al. Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010. Am J Epidemiol 2012; 175:1120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee GM, Romero JR, Bell BP. Postapproval Vaccine Safety Surveillance for COVID-19 Vaccines in the US. JAMA 2020; 324:1937.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Enhanced safety monitoring for COVID-19 vaccines in early phase vaccination. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-09/COVID-03-Shimabukuro.pdf (Accessed on November 18, 2020).
         </li>
         <li class="breakAll">
          Fine PEM, Mulholland K, Scott JA, Edmunds WJ. Community Protection. In: Plotkin’s Vaccines, 7th, Plotkin SA, Orenstein WA, Offit PA, Edwards KM (Eds), Elsevier, 2018. p.1512.
         </li>
         <li class="breakAll">
          Levine EM, Davey AS, Houstan AM. Legal Issues. In: Plotkin’s Vaccines, 7th, Plotkin SA, Orenstein WA, Offit PA, Edwards KM (Eds), Elsevier, 2018. p.1601.
         </li>
         <li class="breakAll">
          Health Resources and Services Administration. Countermeasures Injury Compensation Program. https://www.hrsa.gov/cicp (Accessed on November 20, 2020).
         </li>
         <li class="breakAll">
          World Health Organization. Ten threats to global health in 2019. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019 (Accessed on November 12, 2020).
         </li>
         <li class="breakAll">
          Communication skills for talking about COVID vaccines https://www.vitaltalk.org/wp-content/uploads/Communication-skills-for-the-COVID-vaccine_v1.2-1.pdf (Accessed on January 21, 2021).
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Talking to Recipients about COVID-19 Vaccines. https://www.cdc.gov/vaccines/covid-19/hcp/index.html (Accessed on January 21, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazarus JV, Ratzan SC, Palayew A, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med 2021; 27:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lun P, Ning K, Wang Y, et al. COVID-19 Vaccination Willingness and Reasons for Vaccine Refusal. JAMA Netw Open 2023; 6:e2337909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daly M, Jones A, Robinson E. Public Trust and Willingness to Vaccinate Against COVID-19 in the US From October 14, 2020, to March 29, 2021. JAMA 2021; 325:2397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szilagyi PG, Thomas K, Shah MD, et al. National Trends in the US Public's Likelihood of Getting a COVID-19 Vaccine-April 1 to December 8, 2020. JAMA 2020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gadoth A, Halbrook M, Martin-Blais R, et al. Cross-sectional Assessment of COVID-19 Vaccine Acceptance Among Health Care Workers in Los Angeles. Ann Intern Med 2021; 174:882.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaw J, Stewart T, Anderson KB, et al. Assessment of US Healthcare Personnel Attitudes Towards Coronavirus Disease 2019 (COVID-19) Vaccination in a Large University Healthcare System. Clin Infect Dis 2021; 73:1776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen KH, Srivastav A, Razzaghi H, et al. COVID-19 Vaccination Intent, Perceptions, and Reasons for Not Vaccinating Among Groups Prioritized for Early Vaccination - United States, September and December 2020. MMWR Morb Mortal Wkly Rep 2021; 70:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher KA, Bloomstone SJ, Walder J, et al. Attitudes Toward a Potential SARS-CoV-2 Vaccine : A Survey of U.S. Adults. Ann Intern Med 2020; 173:964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Mohandes A, White TM, Wyka K, et al. COVID-19 vaccine acceptance among adults in four major US metropolitan areas and nationwide. Sci Rep 2021; 11:21844.
          </a>
         </li>
         <li class="breakAll">
          Twentyman E. Updates to Interim Clinical Considerations for Use of COVID-19 Vaccines. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-04-19/07-COVID-Twentyman-508.pdf (Accessed on April 20, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinclair AH, Taylor MK, Weitz JS, et al. Reasons for Receiving or Not Receiving Bivalent COVID-19 Booster Vaccinations Among Adults - United States, November 1-December 10, 2022. MMWR Morb Mortal Wkly Rep 2023; 72:73.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 129849 Version 184.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : World Health Organization. Draft landscape of COVID-19 candidate vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (Accessed on October 20, 2020).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32015507" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : A pneumonia outbreak associated with a new coronavirus of probable bat origin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32967006" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : SARS-CoV-2 vaccines in development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8277200" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17167134" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32365191" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32385100" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Rapid COVID-19 vaccine development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32785649" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : COVID-19 Vaccines: Should We Fear ADE?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32785649" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : COVID-19 Vaccines: Should We Fear ADE?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32785649" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : COVID-19 Vaccines: Should We Fear ADE?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32785649" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : COVID-19 Vaccines: Should We Fear ADE?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32785649" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : COVID-19 Vaccines: Should We Fear ADE?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32785649" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : COVID-19 Vaccines: Should We Fear ADE?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32785649" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : COVID-19 Vaccines: Should We Fear ADE?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32785649" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : COVID-19 Vaccines: Should We Fear ADE?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32785649" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : COVID-19 Vaccines: Should We Fear ADE?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34496194" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33964222" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33901420" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33626250" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34741818" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34928700" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System : A Target Trial Emulation Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35324878" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death - United States, March 2021-January 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36074486" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36074486" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36074486" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36074486" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37262007" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections Among Blood Donors, by COVID-19 Vaccination Status - United States, April 2021-September 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37074868" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37796744" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : COVID-19-Associated Hospitalizations Among U.S. Adults Aged≥65 Years - COVID-NET, 13 States, January-August 2023.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35081293" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Homologous and Heterologous Covid-19 Booster Vaccinations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35045226" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35550261" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35139265" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35358170" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson&amp;Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35613039" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34774197" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36595296" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Examination of Adverse Reactions After COVID-19 Vaccination Among Patients With a History of Multisystem Inflammatory Syndrome in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34724529" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33931567" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33766944" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34670040" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a Prison.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35172072" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35157493" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine : A Retrospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35172051" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35366959" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35366962" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36239934" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36286260" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Protection against Omicron from Vaccination and Previous Infection in a Prison System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34724027" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35613036" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34735425" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35085222" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35085222" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33691060" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33930320" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33930320" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33930320" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33999127" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34358310" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34245907" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34735426" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34324256" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34962505" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35236664" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35991760" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : COVID-19 vaccine effectiveness against omicron (B.1.1.529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33950155" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34029487" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34270933" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Antibody response after second BNT162b2 dose in allogeneic HSCT recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34166499" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34514436" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34962357" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35085218" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36264840" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34161700" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34125572" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34057463" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34297036" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34379917" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35007148" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35007148" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37414897" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34043894" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36791162" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34379915" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35544369" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36260859" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34752019" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35560036" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35298453" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35353976" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : BNT162b2 Protection against the Omicron Variant in Children and Adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35446827" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Hospitalizations of Children Aged 5-11 Years with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 2020-February 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35559959" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Risk of Infection and Hospitalization Among Vaccinated and Unvaccinated Children and Adolescents in New York After the Emergence of the Omicron Variant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35767475" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35780801" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35857701" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36069811" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Effects of Vaccination and Previous Infection on Omicron Infections in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36322837" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Covid-19 Vaccine Protection among Children and Adolescents in Qatar.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36622683" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : BNT162b2 Vaccine Effectiveness Against the SARS-CoV-2 Omicron Variant in Children Aged 5 to 11 Years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36689319" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Assessment of Efficacy and Safety of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37084750" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Safety and effectiveness of vaccines against COVID-19 in children aged 5-11 years: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37336222" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37712905" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Receipt of BNT162b2 Vaccine and COVID-19 Ambulatory Visits in US Children Younger Than 5 Years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32945335" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32945335" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35585684" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Risk of Myopericarditis After COVID-19 Vaccination in Danish Children Aged 5 to 11 Years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35585684" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Risk of Myopericarditis After COVID-19 Vaccination in Danish Children Aged 5 to 11 Years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35585684" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Risk of Myopericarditis After COVID-19 Vaccination in Danish Children Aged 5 to 11 Years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34968370" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34968370" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34968370" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34968370" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34034858" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Multisystem Inflammatory Syndrome after SARS-CoV-2 Infection and COVID-19 Vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35216660" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36821777" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Surveillance for Multisystem Inflammatory Syndrome in US Children Aged 5-11 Years Who Received Pfizer-BioNTech COVID-19 Vaccine, November 2021 through March 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34928295" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Multisystem Inflammatory Syndrome in Children by COVID-19 Vaccination Status of Adolescents in France.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35025852" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35025852" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24759657" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Benefits from immunization during the vaccines for children program era - United States, 1994-2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36269359" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Association of Symptoms After COVID-19 Vaccination With Anti-SARS-CoV-2 Antibody Response in the Framingham Heart Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34398173" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Association of Vaccine Type and Prior SARS-CoV-2 Infection With Symptoms and Antibody Measurements Following Vaccination Among Health Care Workers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33818592" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19837254" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24897504" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Effects of prophylactic and therapeutic paracetamol treatment during vaccination on hepatitis B antibody levels in adults: two open-label, randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18451756" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Syncope after vaccination--United States, January 2005-July 2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34105247" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34125573" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Severe Exacerbations of Systemic Capillary Leak Syndrome After COVID-19 Vaccination: A Case Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34125573" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Severe Exacerbations of Systemic Capillary Leak Syndrome After COVID-19 Vaccination: A Case Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33657292" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33882229" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Delayed Large Local Reactions to mRNA Vaccines. Reply.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18507871" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Safety of intramuscular influenza vaccine in patients receiving oral anticoagulation therapy: a single blinded multi-centre randomized controlled clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37220941" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Adverse outcomes of SARS-CoV-2 infection with delta and omicron variants in vaccinated versus unvaccinated US veterans: retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37220941" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Adverse outcomes of SARS-CoV-2 infection with delta and omicron variants in vaccinated versus unvaccinated US veterans: retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34710075" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : COVID-19 Vaccination and Non-COVID-19 Mortality Risk - Seven Integrated Health Care Organizations, United States, December 14, 2020-July 31, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34525277" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34551225" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34910859" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37319029" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Notes from the Field: Comparison of COVID-19 Mortality Rates Among Adults Aged≥65 Years Who Were Unvaccinated and Those Who Received a Bivalent Booster Dose Within the Preceding 6 Months - 20 U.S. Jurisdictions, September 18, 2022-April 1, 2023.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36155617" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34043615" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34320281" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34734975" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35867050" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Association Between Vaccination and Acute Myocardial Infarction and Ischemic Stroke After COVID-19 Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34990440" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Risk Factors for Severe COVID-19 Outcomes Among Persons Aged≥18 Years Who Completed a Primary COVID-19 Vaccination Series - 465 Health Care Facilities, United States, December 2020-October 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36813689" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Impact of Vaccination on Major Adverse Cardiovascular Events in Patients With COVID-19 Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34756204" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34437524" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34706170" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Waning Immunity after the BNT162b2 Vaccine in Israel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35021002" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35176007" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36191948" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37104244" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period - IVY Network, 19 U.S. States, February 1, 2022-January 31, 2023.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37453440" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36580424" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Hospitalization Among Immunocompetent Adults Aged≥65 Years - IVY Network, 18 States, September 8-November 30, 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36580430" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36734847" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Effectiveness of Bivalent Boosters against Severe Omicron Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36757865" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination - 24 U.S. Jurisdictions, October 3, 2021-December 24, 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37062302" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34879188" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Protection against Covid-19 by BNT162b2 Booster across Age Groups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34756184" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34879190" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : BNT162b2 Vaccine Booster and Mortality Due to Covid-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36215715" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36717123" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Booster vaccination with inactivated whole-virus or mRNA vaccines and COVID-19-related deaths among people with multimorbidity: a cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35381126" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Protection by a Fourth Dose of BNT162b2 against Omicron in Israel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35468276" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35417631" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37280047" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Long-term Real-world Protection Afforded by Third mRNA Doses Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections, Coronavirus Disease 19-related Emergency Attendances and Hospitalizations Amongst Older Singaporeans During an Omicron XBB Wave.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35060999" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35085224" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35189624" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35264324" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35263534" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35249272" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35704396" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35704396" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34965358" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36264830" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36780914" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37227984" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37227984" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33301246" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33301246" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33378609" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34192426" id="rid183" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          184 : Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37099299" id="rid184" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          185 : Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35157002" id="rid185" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          186 : Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34437517" id="rid186" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          187 : New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status - New York, May 3-July 25, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34437519" id="rid187" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          188 : Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34614327" id="rid188" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          189 : Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34619098" id="rid189" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          190 : Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34731553" id="rid190" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          191 : Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34735261" id="rid191" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          192 : SARS-CoV-2 vaccine protection and deaths among US veterans during 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34819275" id="rid192" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          193 : Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35081294" id="rid193" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          194 : Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35131043" id="rid194" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          195 : Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35202601" id="rid195" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          196 : Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37133863" id="rid196" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          197 : Evaluation of Waning of SARS-CoV-2 Vaccine-Induced Immunity: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37792377" id="rid197" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          198 : Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373 Against COVID-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36454688" id="rid198" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          199 : Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37043647" id="rid199" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          200 : Durability of Bivalent Boosters against Omicron Subvariants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35320659" id="rid200" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          201 : Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35006256" id="rid201" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          202 : Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35653123" id="rid202" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          203 : Association Between COVID-19 Booster Vaccination and Omicron Infection in a Highly Vaccinated Cohort of Players and Staff in the National Basketball Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36096146" id="rid203" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          204 : Initial protection against SARS-CoV-2 omicron lineage infection in children and adolescents by BNT162b2 in Israel: an observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37351451" id="rid204" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          205 : Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34480857" id="rid205" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          206 : Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35614233" id="rid206" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          207 : Long COVID after breakthrough SARS-CoV-2 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35796131" id="rid207" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          208 : Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36936268" id="rid208" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          209 : Effect of covid-19 vaccination on long covid: systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34986294" id="rid209" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          210 : Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34756186" id="rid210" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          211 : Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34941024" id="rid211" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          212 : Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35395151" id="rid212" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          213 : Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35608859" id="rid213" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          214 : Transmission and Infectious SARS-CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated Individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34826623" id="rid214" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          215 : Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36593393" id="rid215" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          216 : Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37093964" id="rid216" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          217 : Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Delta and Omicron Infection and Infectiousness Within Households in the Netherlands Between July 2021 and August 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37673865" id="rid217" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          218 : Effect of SARS-CoV-2 prior infection and mRNA vaccination on contagiousness and susceptibility to infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34529642" id="rid218" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          219 : Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19-Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance - Nine States, June-August 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34551224" id="rid219" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          220 : Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34942066" id="rid220" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          221 : Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34882654" id="rid221" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          222 : Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35045222" id="rid222" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          223 : Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35050314" id="rid223" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          224 : Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35501319" id="rid224" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          225 : Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36921925" id="rid225" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          226 : Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35696161" id="rid226" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          227 : Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34588689" id="rid227" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          228 : Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34812653" id="rid228" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          229 : Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34648302" id="rid229" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          230 : mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35102312" id="rid230" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          231 : Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35102311" id="rid231" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          232 : T cell responses to SARS-CoV-2 spike cross-recognize Omicron.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35139340" id="rid232" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          233 : SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35139340" id="rid233" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          234 : SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35139340" id="rid234" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          235 : SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35139340" id="rid235" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          236 : SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33630816" id="rid236" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          237 : First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33630816" id="rid237" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          238 : First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36634021" id="rid238" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          239 : Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36327162" id="rid239" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          240 : Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged≥12 Years - United States, August 31-October 23, 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37278199" id="rid240" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          241 : Safety of COVID-19 mRNA Vaccination Among Young Children in the Vaccine Safety Datalink.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37278199" id="rid241" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          242 : Safety of COVID-19 mRNA Vaccination Among Young Children in the Vaccine Safety Datalink.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34237049" id="rid242" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          243 : Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34237049" id="rid243" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          244 : Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35076665" id="rid244" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          245 : Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36191323" id="rid245" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          246 : Incidence of Myocarditis/Pericarditis Following mRNA COVID-19 Vaccination Among Children and Younger Adults in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34614328" id="rid246" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          247 : Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34614329" id="rid247" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          248 : Myocarditis after Covid-19 Vaccination in a Large Health Care Organization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35073155" id="rid248" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          249 : Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine : A Case-Control Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35081295" id="rid249" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          250 : Myocarditis after BNT162b2 Vaccination in Israeli Adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36848096" id="rid250" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          251 : Myocarditis or Pericarditis Events After BNT162b2 Vaccination in Individuals Aged 12 to 17 Years in Ontario, Canada.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34916207" id="rid251" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          252 : SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34916207" id="rid252" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          253 : SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35442390" id="rid253" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          254 : SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35752614" id="rid254" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          255 : Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35749115" id="rid255" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          256 : Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35389977" id="rid256" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          257 : Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination - PCORnet, United States, January 2021-January 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36260842" id="rid257" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          258 : Myocarditis after BNT162b2 Vaccination in Israeli Adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36936260" id="rid258" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          259 : Clinical outcomes of myocarditis after SARS-CoV-2 mRNA vaccination in four Nordic countries: population based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34407340" id="rid259" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          260 : Myocarditis after Covid-19 mRNA Vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37094872" id="rid260" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          261 : Persistent myopericarditis after heterologous SARS-CoV-2 mRNA vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37264895" id="rid261" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          262 : COVID-19 vaccination-related myocarditis: a Korean nationwide study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34865500" id="rid262" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          263 : Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults: Suspected Myocarditis After COVID-19 Vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34865500" id="rid263" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          264 : Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults: Suspected Myocarditis After COVID-19 Vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34865500" id="rid264" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          265 : Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults: Suspected Myocarditis After COVID-19 Vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33835768" id="rid265" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          266 : Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33835769" id="rid266" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          267 : Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33852795" id="rid267" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          268 : Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33929487" id="rid268" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          269 : US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34379914" id="rid269" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          270 : Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34379914" id="rid270" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          271 : Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33914723" id="rid271" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          272 : Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson&amp;Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33914723" id="rid272" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          273 : Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson&amp;Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33914723" id="rid273" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          274 : Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson&amp;Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34446426" id="rid274" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          275 : Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34446426" id="rid275" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          276 : Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34446426" id="rid276" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          277 : Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34446426" id="rid277" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          278 : Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34446426" id="rid278" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          279 : Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32840686" id="rid279" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          280 : Guillain-Barrésyndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33228253" id="rid280" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          281 : COVID-19 as a Trigger of Recurrent Guillain-BarréSyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34697502" id="rid281" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          282 : Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34617967" id="rid282" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          283 : Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-BarréSyndrome, February-July 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35471572" id="rid283" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          284 : Incidence of Guillain-BarréSyndrome After COVID-19 Vaccination in the Vaccine Safety Datalink.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36723942" id="rid284" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          285 : Reports of Guillain-BarréSyndrome After COVID-19 Vaccination in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34383735" id="rid285" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          286 : Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson&amp;Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35180300" id="rid286" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          287 : COVID-19 vaccination and Guillain-Barrésyndrome: analyses using the National Immunoglobulin Database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34114269" id="rid287" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          288 : Guillain-BarréSyndrome Variant Occurring after SARS-CoV-2 Vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34114256" id="rid288" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          289 : Guillain-BarréSyndrome following ChAdOx1-S/nCoV-19 Vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35296468" id="rid289" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          290 : Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35296468" id="rid290" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          291 : Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35296468" id="rid291" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          292 : Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35296468" id="rid292" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          293 : Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35296468" id="rid293" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          294 : Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36988584" id="rid294" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          295 : Stroke, Myocardial Infarction, and Pulmonary Embolism after Bivalent Booster.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37318811" id="rid295" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          296 : BA.1 Bivalent COVID-19 Vaccine Use and Stroke in England.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33388478" id="rid296" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          297 : mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33388478" id="rid297" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          298 : mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33641268" id="rid298" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          299 : Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34477808" id="rid299" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          300 : Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33576785" id="rid300" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          301 : Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34153517" id="rid301" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          302 : The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34533570" id="rid302" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          303 : Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36532656" id="rid303" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          304 : The conundrum of COVID-19 mRNA vaccine-induced anaphylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35190259" id="rid304" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          305 : Investigation of the incidence of immunisation stress-related response following COVID-19 vaccination in healthcare workers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33444297" id="rid305" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          306 : Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35051292" id="rid306" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          307 : A Prospective Cohort Study of COVID-19 Vaccination, SARS-CoV-2 Infection, and Fertility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34734259" id="rid307" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          308 : Effects of COVID-19 and mRNA vaccines on human fertility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34734259" id="rid308" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          309 : Effects of COVID-19 and mRNA vaccines on human fertility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21596088" id="rid309" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          310 : Monitoring vaccine safety using the Vaccine Safety Datalink: utilizing immunization registries for pandemic influenza.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22582207" id="rid310" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          311 : Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33064152" id="rid311" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          312 : Postapproval Vaccine Safety Surveillance for COVID-19 Vaccines in the US.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33064152" id="rid312" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          313 : Postapproval Vaccine Safety Surveillance for COVID-19 Vaccines in the US.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33064152" id="rid313" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          314 : Postapproval Vaccine Safety Surveillance for COVID-19 Vaccines in the US.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33064152" id="rid314" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          315 : Postapproval Vaccine Safety Surveillance for COVID-19 Vaccines in the US.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33064152" id="rid315" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          316 : Postapproval Vaccine Safety Surveillance for COVID-19 Vaccines in the US.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33064152" id="rid316" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          317 : Postapproval Vaccine Safety Surveillance for COVID-19 Vaccines in the US.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33064152" id="rid317" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          318 : Postapproval Vaccine Safety Surveillance for COVID-19 Vaccines in the US.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33064152" id="rid318" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          319 : Postapproval Vaccine Safety Surveillance for COVID-19 Vaccines in the US.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33082575" id="rid319" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          320 : A global survey of potential acceptance of a COVID-19 vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37856125" id="rid320" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          321 : COVID-19 Vaccination Willingness and Reasons for Vaccine Refusal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34028495" id="rid321" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          322 : Public Trust and Willingness to Vaccinate Against COVID-19 in the US From October 14, 2020, to March 29, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33372943" id="rid322" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          323 : National Trends in the US Public's Likelihood of Getting a COVID-19 Vaccine-April 1 to December 8, 2020.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33556267" id="rid323" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          324 : Cross-sectional Assessment of COVID-19 Vaccine Acceptance Among Health Care Workers in Los Angeles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33491049" id="rid324" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          325 : Assessment of US Healthcare Personnel Attitudes Towards Coronavirus Disease 2019 (COVID-19) Vaccination in a Large University Healthcare System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33571174" id="rid325" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          326 : COVID-19 Vaccination Intent, Perceptions, and Reasons for Not Vaccinating Among Groups Prioritized for Early Vaccination - United States, September and December 2020.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32886525" id="rid326" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          327 : Attitudes Toward a Potential SARS-CoV-2 Vaccine : A Survey of U.S. Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34737319" id="rid327" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          328 : COVID-19 vaccine acceptance among adults in four major US metropolitan areas and nationwide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34737319" id="rid328" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          329 : COVID-19 vaccine acceptance among adults in four major US metropolitan areas and nationwide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36656784" id="rid329" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          330 : Reasons for Receiving or Not Receiving Bivalent COVID-19 Booster Vaccinations Among Adults - United States, November 1-December 10, 2022.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
